{"/2020/11/27/sbiobertresolve_cpt_en.html":[],"/2021/05/16/sbiobertresolve_cpt_en.html":[],"/2021/05/30/sbiobertresolve_cpt_augmented_en.html":[],"/2021/05/30/sbiobertresolve_cpt_procedures_augmented_en.html":[],"/2021/06/15/sbiobertresolve_cpt_procedures_augmented_en.html":[],"/2021/07/02/sbiobertresolve_cpt_procedures_measurements_augmented_en.html":[],"/2022/02/01/ner_supplement_clinical_en.html":["https://github.com/explosion/healthsea/tree/main/project/assets/ner"],"/2022/02/01/sbiobertresolve_clinical_abbreviation_acronym_en.html":[],"/2022/02/07/bert_sequence_classifier_pico_biobert_en.html":[],"/2022/02/08/ner_nature_nero_clinical_en.html":["https://www.nature.com/articles/s41540-021-00200-x","https://static-content.springer.com/esm/art%3A10.1038%2Fs41540-021-00200-x/MediaObjects/41540_2021_200_MOESM1_ESM.pdf"],"/2022/02/08/bert_sequence_classifier_ade_en.html":[],"/2022/02/08/bert_sequence_classifier_gender_biobert_en.html":[],"/2022/02/08/distilbert_sequence_classifier_ade_en.html":[],"/2022/02/09/bert_token_classifier_ner_supplement_en.html":["https://github.com/explosion/healthsea/tree/main/project/assets/ner"],"/2022/02/11/ner_deid_generic_fr.html":["https://metatext.io/datasets/wikiner","https://www.data.gouv.fr/fr/datasets/entreprises-immatriculees-en-2017/","https://salesdorado.com/fichiers-prospection/hopitaux/"],"/2022/02/11/ner_deid_subentity_fr.html":["https://metatext.io/datasets/wikiner","https://www.data.gouv.fr/fr/datasets/entreprises-immatriculees-en-2017/","https://salesdorado.com/fichiers-prospection/hopitaux/"],"/2022/02/14/ner_deid_subentity_fr.html":["https://metatext.io/datasets/wikiner","https://www.data.gouv.fr/fr/datasets/entreprises-immatriculees-en-2017/","https://salesdorado.com/fichiers-prospection/hopitaux/"],"/2022/02/15/ner_deid_generic_augmented_es.html":["https://www.clips.uantwerpen.be/conll2002/ner/data/","https://temu.bsc.es/meddoprof/data/","https://temu.bsc.es/meddocan/"],"/2022/02/15/ner_deid_generic_roberta_augmented_es.html":["https://www.clips.uantwerpen.be/conll2002/ner/data/","https://temu.bsc.es/meddoprof/data/","https://temu.bsc.es/meddocan/"],"/2022/02/15/ner_deid_subentity_augmented_es.html":["https://www.clips.uantwerpen.be/conll2002/ner/data/","https://temu.bsc.es/meddoprof/data/","https://temu.bsc.es/meddocan/"],"/2022/02/15/ner_deid_subentity_roberta_augmented_es.html":["https://www.clips.uantwerpen.be/conll2002/ner/data/","https://temu.bsc.es/meddoprof/data/","https://temu.bsc.es/meddocan/"],"/2022/02/16/ner_deid_generic_augmented_es.html":["https://www.clips.uantwerpen.be/conll2002/ner/data/","https://temu.bsc.es/meddoprof/data/","https://temu.bsc.es/meddocan/"],"/2022/02/16/ner_deid_generic_roberta_augmented_es.html":["https://www.clips.uantwerpen.be/conll2002/ner/data/","https://temu.bsc.es/meddoprof/data/","https://temu.bsc.es/meddocan/"],"/2022/02/16/ner_deid_subentity_augmented_es.html":["https://www.clips.uantwerpen.be/conll2002/ner/data/","https://temu.bsc.es/meddoprof/data/","https://temu.bsc.es/meddocan/"],"/2022/02/16/ner_deid_subentity_roberta_augmented_es.html":["https://www.clips.uantwerpen.be/conll2002/ner/data/","https://temu.bsc.es/meddoprof/data/","https://temu.bsc.es/meddocan/"],"/2022/03/01/sbiobertresolve_atc_en_2_4.html":[],"/2022/03/01/sbiobertresolve_atc_en_3_0.html":[],"/2022/03/01/bert_sequence_classifier_rct_biobert_en_2_4.html":["https://arxiv.org/abs/1710.06071"],"/2022/03/01/bert_sequence_classifier_rct_biobert_en_3_0.html":["https://arxiv.org/abs/1710.06071"],"/2022/03/17/assertion_dl_scope_L10R10_en_2_4.html":["https://portal.dbmi.hms.harvard.edu/projects/n2c2-nlp/"],"/2022/03/17/assertion_dl_scope_L10R10_en_3_0.html":["https://portal.dbmi.hms.harvard.edu/projects/n2c2-nlp/"],"/2022/03/22/bert_token_classifier_drug_development_trials_en_3_0.html":[],"/2022/03/22/bert_token_classifier_drug_development_trials_en_2_4.html":[],"/2022/03/22/ner_deid_subentity_it_3_0.html":["https://ieeexplore.ieee.org/document/9335570"],"/2022/03/23/assertion_dl_biobert_scope_L10R10_en_3_0.html":["https://portal.dbmi.hms.harvard.edu/projects/n2c2-nlp/"],"/2022/03/24/assertion_dl_biobert_scope_L10R10_en_2_4.html":["https://portal.dbmi.hms.harvard.edu/projects/n2c2-nlp/"],"/2022/03/25/ner_deid_generic_it_2_4.html":["https://ieeexplore.ieee.org/document/9335570"],"/2022/03/25/ner_deid_generic_it_3_0.html":["https://ieeexplore.ieee.org/document/9335570"],"/2022/03/25/ner_deid_subentity_it_2_4.html":["https://ieeexplore.ieee.org/document/9335570"],"/2022/04/05/re_zeroshot_biobert_en_3_0.html":[],"/2022/04/11/spellcheck_clinical_en_3_0.html":[],"/2022/04/13/ner_deid_generic_pt_3_0.html":[],"/2022/04/13/ner_deid_subentity_pt_3_0.html":[],"/2022/04/14/spellcheck_clinical_en_2_4.html":[],"/2022/04/18/sbiobertresolve_ndc_en_2_4.html":[],"/2022/04/18/spellcheck_clinical_en_2_4.html":[],"/2022/04/25/bert_sequence_classifier_binary_rct_biobert_en_3_0.html":["https://arxiv.org/abs/1710.06071"],"/2022/05/10/sbiobertresolve_cpt_procedures_measurements_augmented_en_3_0.html":[],"/2022/05/10/ner_biomedical_bc2gm_en_3_0.html":["https://metatext.io/datasets/biocreative-ii-gene-mention-recognition-(bc2gm))"],"/2022/05/11/abbreviation_mapper_en_3_0.html":["https://www.johnsnowlabs.com/marketplace/list-of-abbreviations-and-acronyms-for-medical-regulatory-activities/"],"/2022/05/11/ner_biomedical_bc2gm_en_2_4.html":["https://metatext.io/datasets/biocreative-ii-gene-mention-recognition-(bc2gm))"],"/2022/05/27/rct_binary_classifier_biobert_en_3_0.html":["https://arxiv.org/abs/1710.06071"],"/2022/05/27/rct_binary_classifier_use_en_3_0.html":["https://arxiv.org/abs/1710.06071"],"/2022/06/06/sbiobertresolve_icdo_augmented_en_3_0.html":["https://apps.who.int/iris/bitstream/handle/10665/96612/9789241548496_eng.pdf"],"/2022/06/18/bert_token_classifier_drug_development_trials_en_3_0.html":[],"/2022/06/22/ner_living_species_bert_es_3_0.html":["https://temu.bsc.es/livingner/"],"/2022/06/22/ner_living_species_bert_pt_3_0.html":["https://temu.bsc.es/livingner/2022/05/03/multilingual-corpus/"],"/2022/06/22/ner_living_species_biobert_en_3_0.html":["https://temu.bsc.es/livingner/2022/05/03/multilingual-corpus/"],"/2022/06/22/ner_living_species_en_3_0.html":["https://temu.bsc.es/livingner/2022/05/03/multilingual-corpus/"],"/2022/06/22/ner_living_species_es_3_0.html":["https://temu.bsc.es/livingner/"],"/2022/06/22/ner_living_species_pt_3_0.html":["https://temu.bsc.es/livingner/2022/05/03/multilingual-corpus/"],"/2022/06/22/ner_living_species_roberta_es_3_0.html":["https://temu.bsc.es/livingner/"],"/2022/06/22/ner_living_species_roberta_pt_3_0.html":["https://temu.bsc.es/livingner/2022/05/03/multilingual-corpus/"],"/2022/06/22/ner_clinical_trials_abstracts_en_3_0.html":["https://pub.uni-bielefeld.de/record/2939477"],"/2022/06/23/ner_living_species_bert_fr_3_0.html":["https://temu.bsc.es/livingner/2022/05/03/multilingual-corpus/"],"/2022/06/23/ner_living_species_bert_it_3_0.html":["https://temu.bsc.es/livingner/2022/05/03/multilingual-corpus/"],"/2022/06/23/ner_living_species_bert_ro_3_0.html":["https://temu.bsc.es/livingner/2022/05/03/multilingual-corpus/"],"/2022/06/23/ner_living_species_ca_3_0.html":["https://temu.bsc.es/livingner/2022/05/03/multilingual-corpus/"],"/2022/06/23/ner_living_species_fr_3_0.html":["https://temu.bsc.es/livingner/2022/05/03/multilingual-corpus/"],"/2022/06/23/ner_living_species_gl_3_0.html":["https://temu.bsc.es/livingner/2022/05/03/multilingual-corpus/"],"/2022/06/23/ner_living_species_it_3_0.html":["https://temu.bsc.es/livingner/2022/05/03/multilingual-corpus/"],"/2022/06/26/abbreviation_mapper_en_3_0.html":["https://www.johnsnowlabs.com/marketplace/list-of-abbreviations-and-acronyms-for-medical-regulatory-activities/"],"/2022/06/26/icdo_snomed_mapper_en_3_0.html":[],"/2022/06/26/rxnorm_umls_mapper_en_3_0.html":[],"/2022/06/26/snomed_icd10cm_mapper_en_3_0.html":[],"/2022/06/26/bert_token_classifier_ner_living_species_en_3_0.html":["https://temu.bsc.es/livingner/2022/05/03/multilingual-corpus/"],"/2022/06/27/bert_token_classifier_ner_living_species_es_3_0.html":["https://temu.bsc.es/livingner/"],"/2022/06/27/bert_token_classifier_ner_living_species_it_3_0.html":["https://temu.bsc.es/livingner/2022/05/03/multilingual-corpus/"],"/2022/06/27/bert_token_classifier_ner_living_species_pt_3_0.html":["https://temu.bsc.es/livingner/2022/05/03/multilingual-corpus/"],"/2022/06/27/ner_deid_bert_subentity_ro_3_0.html":[],"/2022/06/27/ner_deid_subentity_bert_ro_3_0.html":[],"/2022/06/27/ner_deid_subentity_ro_3_0.html":[],"/2022/06/27/ner_deid_w2v_subentity_ro_3_0.html":[],"/2022/06/28/ner_pathogen_en_3_0.html":["https://www.kaggle.com/datasets/finalepoch/medical-ner"],"/2022/06/28/bert_sequence_classifier_stress_en_3_0.html":["https://arxiv.org/abs/1911.00133"],"/2022/06/29/bert_token_classifier_ner_clinical_trials_abstracts_en_3_0.html":["https://pub.uni-bielefeld.de/record/2939477"],"/2022/07/05/sbiobertresolve_umls_clinical_drugs_en_3_0.html":["https://www.nlm.nih.gov/research/umls/index.html"],"/2022/07/05/sbiobertresolve_umls_findings_en_3_0.html":["findings.https://www.nlm.nih.gov/research/umls/index.html"],"/2022/07/06/umls_clinical_drugs_mapper_en_3_0.html":["https://www.nlm.nih.gov/research/umls/index.html"],"/2022/07/06/ner_deid_generic_bert_ro_3_0.html":[],"/2022/07/08/umls_clinical_findings_mapper_en_3_0.html":["findings.https://www.nlm.nih.gov/research/umls/index.html"],"/2022/07/08/ner_deid_generic_ro_3_0.html":[],"/2022/07/11/umls_disease_syndrome_mapper_en_3_0.html":["https://www.nlm.nih.gov/research/umls/index.html"],"/2022/07/11/umls_drug_substance_mapper_en_3_0.html":["https://www.nlm.nih.gov/research/umls/index.html"],"/2022/07/11/umls_major_concepts_mapper_en_3_0.html":["https://www.nlm.nih.gov/research/umls/index.html"],"/2022/07/25/bert_token_classifier_ner_anatem_en_3_0.html":["https://github.com/cambridgeltl/MTL-Bioinformatics-2016"],"/2022/07/25/bert_token_classifier_ner_bc2gm_gene_en_3_0.html":["https://github.com/cambridgeltl/MTL-Bioinformatics-2016"],"/2022/07/25/bert_token_classifier_ner_bc4chemd_chemicals_en_3_0.html":["https://github.com/cambridgeltl/MTL-Bioinformatics-2016"],"/2022/07/25/bert_token_classifier_ner_bc5cdr_chemicals_en_3_0.html":["https://github.com/cambridgeltl/MTL-Bioinformatics-2016"],"/2022/07/25/bert_token_classifier_ner_bc5cdr_disease_en_3_0.html":["https://github.com/cambridgeltl/MTL-Bioinformatics-2016"],"/2022/07/25/bert_token_classifier_ner_jnlpba_cellular_en_3_0.html":["https://github.com/cambridgeltl/MTL-Bioinformatics-2016"],"/2022/07/25/bert_token_classifier_ner_linnaeus_species_en_3_0.html":["https://github.com/cambridgeltl/MTL-Bioinformatics-2016"],"/2022/07/25/bert_token_classifier_ner_ncbi_disease_en_3_0.html":["https://github.com/cambridgeltl/MTL-Bioinformatics-2016"],"/2022/07/25/bert_token_classifier_ner_species_en_3_0.html":["https://species.jensenlab.org/"],"/2022/07/25/bert_sequence_classifier_health_mentions_en_3_0.html":[],"/2022/07/25/classifierdl_health_mentions_en_3_0.html":[],"/2022/07/26/bert_sequence_classifier_exact_age_reddit_en_3_0.html":[],"/2022/07/26/ner_living_species_300_es_3_0.html":["https://temu.bsc.es/livingner/"],"/2022/07/27/re_ade_conversational_en_3_0.html":["https://healthlanguageprocessing.org/smm4h-2022/"],"/2022/07/28/classifierdl_vaccine_sentiment_en_3_0.html":[],"/2022/07/28/bert_sequence_classifier_self_reported_partner_violence_tweet_en_3_0.html":["https://healthlanguageprocessing.org/smm4h-2022/"],"/2022/07/28/bert_sequence_classifier_vaccine_sentiment_en_3_0.html":[],"/2022/07/29/bert_sequence_classifier_self_reported_vaccine_status_tweet_en_3_0.html":["https://healthlanguageprocessing.org/smm4h-2022/"],"/2022/08/01/bert_sequence_classifier_covid_sentiment_en_3_0.html":[],"/2022/08/08/bert_sequence_classifier_health_mandates_premise_tweet_en_3_0.html":[],"/2022/08/08/bert_sequence_classifier_health_mandates_stance_tweet_en_3_0.html":[],"/2022/08/09/bert_sequence_classifier_depression_twitter_en_3_0.html":[],"/2022/08/09/finclf_bank_complaints_en_3_2.html":["https://www.consumerfinance.gov/data-research/consumer-complaints/download-the-data"],"/2022/08/09/finclf_distilroberta_sentiment_analysis_en_3_2.html":[],"/2022/08/09/finmapper_nasdaq_companyname_en_3_2.html":["https://data.world/johnsnowlabs/list-of-companies-in-nasdaq-exchanges"],"/2022/08/09/finmapper_nasdaq_ticker_en_3_2.html":["https://data.world/johnsnowlabs/list-of-companies-in-nasdaq-exchanges"],"/2022/08/09/finner_deid_en_3_2.html":[],"/2022/08/09/finner_roberta_ticker_en_3_2.html":["https://www.kaggle.com/omermetinn/tweets-about-the-top-companies-from-2015-to-2020"],"/2022/08/09/finner_ticker_en_3_2.html":["https://www.kaggle.com/omermetinn/tweets-about-the-top-companies-from-2015-to-2020"],"/2022/08/09/finqa_roberta_en_3_2.html":[],"/2022/08/09/legclf_conventions_en_3_2.html":["https://huggingface.co/hackathon-pln-es/jurisbert-class-tratados-internacionales-sistema-universal),","https://www.un.org/es/events/childrenday/pdf/derechos.pdf"],"/2022/08/09/legclf_human_rights_en_3_2.html":["https://huggingface.co/hackathon-pln-es/jurisbert-clas-art-convencion-americana-dh","https://www.ohchr.org/sites/default/files/UDHR/Documents/UDHR_Translations/spn.pdf"],"/2022/08/09/legner_cuad_silver_en_3_2.html":[],"/2022/08/09/legner_deid_en_3_2.html":[],"/2022/08/09/legqa_bert_en_3_2.html":[],"/2022/08/09/legqa_bert_large_en_3_2.html":[],"/2022/08/09/legqa_roberta_en_3_2.html":[],"/2022/08/10/bert_sequence_classifier_depression_binary_en_3_0.html":[],"/2022/08/10/bert_sequence_classifier_health_mentions_bert_de_3_0.html":[],"/2022/08/10/bert_sequence_classifier_health_mentions_gbert_de_3_0.html":[],"/2022/08/10/bert_sequence_classifier_health_mentions_gbert_large_de_3_0.html":[],"/2022/08/10/bert_sequence_classifier_health_mentions_medbert_de_3_0.html":[],"/2022/08/10/finclf_business_item_en_3_2.html":[],"/2022/08/10/finclf_controls_procedures_item_en_3_2.html":[],"/2022/08/10/finclf_equity_item_en_3_2.html":[],"/2022/08/10/finclf_executives_compensation_item_en_3_2.html":[],"/2022/08/10/finclf_executives_item_en_3_2.html":[],"/2022/08/10/finclf_exhibits_item_en_3_2.html":[],"/2022/08/10/finclf_financial_conditions_item_en_3_2.html":[],"/2022/08/10/finclf_financial_statements_item_en_3_2.html":[],"/2022/08/10/finclf_form_10k_summary_item_en_3_2.html":[],"/2022/08/10/finclf_legal_proceedings_item_en_3_2.html":[],"/2022/08/10/finclf_market_risk_item_en_3_2.html":[],"/2022/08/10/finclf_properties_item_en_3_2.html":[],"/2022/08/10/finclf_risk_factors_item_en_3_2.html":[],"/2022/08/10/finclf_security_ownership_item_en_3_2.html":[],"/2022/08/10/legclf_absence_of_certain_changes_clause_en_3_2.html":[],"/2022/08/10/legclf_acceleration_clause_en_3_2.html":[],"/2022/08/10/legclf_access_clause_en_3_2.html":[],"/2022/08/10/legclf_accounting_terms_clause_en_3_2.html":[],"/2022/08/10/legclf_adjustments_clause_en_3_2.html":[],"/2022/08/10/legclf_agreements_clause_en_3_2.html":[],"/2022/08/10/legclf_amendments_clause_en_3_2.html":[],"/2022/08/10/legclf_application_of_proceeds_clause_en_3_2.html":[],"/2022/08/10/legclf_appointment_clause_en_3_2.html":[],"/2022/08/10/legclf_approvals_clause_en_3_2.html":[],"/2022/08/10/legclf_arbitration_clause_en_3_2.html":[],"/2022/08/10/legclf_assignments_clause_en_3_2.html":[],"/2022/08/10/legclf_authority_clause_en_3_2.html":[],"/2022/08/10/legclf_authorization_clause_en_3_2.html":[],"/2022/08/10/legclf_auto_renewal_clause_en_3_2.html":[],"/2022/08/10/legclf_background_clause_en_3_2.html":[],"/2022/08/10/legclf_bank_accounts_clause_en_3_2.html":[],"/2022/08/10/legclf_bankruptcy_clause_en_3_2.html":[],"/2022/08/10/legclf_base_salary_clause_en_3_2.html":[],"/2022/08/10/legclf_benefits_clause_en_3_2.html":[],"/2022/08/10/legclf_bereavement_leave_clause_en_3_2.html":[],"/2022/08/10/legclf_binding_effect_clause_en_3_2.html":[],"/2022/08/10/legclf_bonus_clause_en_3_2.html":[],"/2022/08/10/legclf_books_and_records_clause_en_3_2.html":[],"/2022/08/10/legclf_brokers_clause_en_3_2.html":[],"/2022/08/10/legclf_cancellation_clause_en_3_2.html":[],"/2022/08/10/legclf_capitalization_clause_en_3_2.html":[],"/2022/08/10/legclf_captions_clause_en_3_2.html":[],"/2022/08/10/legclf_cause_clause_en_3_2.html":[],"/2022/08/10/legclf_certain_definitions_clause_en_3_2.html":[],"/2022/08/10/legclf_certificates_clause_en_3_2.html":[],"/2022/08/10/legclf_change_in_control_clause_en_3_2.html":[],"/2022/08/10/legclf_change_of_control_clause_en_3_2.html":[],"/2022/08/10/legclf_closing_clause_en_3_2.html":[],"/2022/08/10/legclf_collateral_clause_en_3_2.html":[],"/2022/08/10/legclf_compensation_and_benefits_clause_en_3_2.html":[],"/2022/08/10/legclf_compensation_clause_en_3_2.html":[],"/2022/08/10/legclf_compliance_clause_en_3_2.html":[],"/2022/08/10/legclf_compliance_with_laws_clause_en_3_2.html":[],"/2022/08/10/legclf_condemnation_clause_en_3_2.html":[],"/2022/08/10/legclf_conditions_clause_en_3_2.html":[],"/2022/08/10/legclf_conditions_to_effectiveness_clause_en_3_2.html":[],"/2022/08/10/legclf_conduct_of_business_clause_en_3_2.html":[],"/2022/08/10/legclf_confidential_clause_en_3_2.html":[],"/2022/08/10/legclf_conflict_of_interest_clause_en_3_2.html":[],"/2022/08/10/legclf_consents_clause_en_3_2.html":[],"/2022/08/10/legclf_consideration_clause_en_3_2.html":[],"/2022/08/10/legclf_construction_clause_en_3_2.html":[],"/2022/08/10/legclf_contracts_clause_en_3_2.html":[],"/2022/08/10/legclf_contribution_clause_en_3_2.html":[],"/2022/08/10/legclf_cooperation_clause_en_3_2.html":[],"/2022/08/10/legclf_corporate_existence_clause_en_3_2.html":[],"/2022/08/10/legclf_costs_clause_en_3_2.html":[],"/2022/08/10/legclf_counterparts_clause_en_3_2.html":[],"/2022/08/10/legclf_covenants_clause_en_3_2.html":[],"/2022/08/10/legclf_currency_clause_en_3_2.html":[],"/2022/08/10/legclf_death_clause_en_3_2.html":[],"/2022/08/10/legclf_defaults_and_remedies_clause_en_3_2.html":[],"/2022/08/10/legclf_defaults_clause_en_3_2.html":[],"/2022/08/10/legclf_definitions_and_interpretation_clause_en_3_2.html":[],"/2022/08/10/legclf_definitions_clause_en_3_2.html":[],"/2022/08/10/legclf_delegation_of_duties_clause_en_3_2.html":[],"/2022/08/10/legclf_delivery_clause_en_3_2.html":[],"/2022/08/10/legclf_disability_clause_en_3_2.html":[],"/2022/08/10/legclf_disclaimer_clause_en_3_2.html":[],"/2022/08/10/legclf_disclosure_clause_en_3_2.html":[],"/2022/08/10/legclf_dispute_resolution_clause_en_3_2.html":[],"/2022/08/10/legclf_disputes_clause_en_3_2.html":[],"/2022/08/10/legclf_dissolution_clause_en_3_2.html":[],"/2022/08/10/legclf_distributions_clause_en_3_2.html":[],"/2022/08/10/legclf_dividends_clause_en_3_2.html":[],"/2022/08/10/legclf_documents_clause_en_3_2.html":[],"/2022/08/10/legclf_duration_and_termination_clause_en_3_2.html":[],"/2022/08/10/legclf_duration_clause_en_3_2.html":[],"/2022/08/10/legclf_duties_clause_en_3_2.html":[],"/2022/08/10/legclf_effective_date_clause_en_3_2.html":[],"/2022/08/10/legclf_effectiveness_clause_en_3_2.html":[],"/2022/08/10/legclf_employees_clause_en_3_2.html":[],"/2022/08/10/legclf_employment_clause_en_3_2.html":[],"/2022/08/10/legclf_erisa_clause_en_3_2.html":[],"/2022/08/10/legclf_exceptions_clause_en_3_2.html":[],"/2022/08/10/legclf_exclusions_clause_en_3_2.html":[],"/2022/08/10/legclf_exclusivity_clause_en_3_2.html":[],"/2022/08/10/legclf_execution_clause_en_3_2.html":[],"/2022/08/10/legclf_execution_in_counterparts_clause_en_3_2.html":[],"/2022/08/10/legclf_exercise_of_option_clause_en_3_2.html":[],"/2022/08/10/legclf_exhibits_clause_en_3_2.html":[],"/2022/08/10/legclf_expenses_clause_en_3_2.html":[],"/2022/08/10/legclf_fees_clause_en_3_2.html":[],"/2022/08/10/legclf_financial_information_clause_en_3_2.html":[],"/2022/08/10/legclf_financial_statements_clause_en_3_2.html":[],"/2022/08/10/legclf_fiscal_year_clause_en_3_2.html":[],"/2022/08/10/legclf_force_majeure_clause_en_3_2.html":[],"/2022/08/10/legclf_fractional_shares_clause_en_3_2.html":[],"/2022/08/10/legclf_full_disclosure_clause_en_3_2.html":[],"/2022/08/10/legclf_further_assurances_clause_en_3_2.html":[],"/2022/08/10/legclf_general_clause_en_3_2.html":[],"/2022/08/10/legclf_good_reason_clause_en_3_2.html":[],"/2022/08/10/legclf_grant_of_option_clause_en_3_2.html":[],"/2022/08/10/legclf_grant_of_security_interest_clause_en_3_2.html":[],"/2022/08/10/legclf_guarantee_clause_en_3_2.html":[],"/2022/08/10/legclf_headings_clause_en_3_2.html":[],"/2022/08/10/legclf_holidays_clause_en_3_2.html":[],"/2022/08/10/legclf_illegality_clause_en_3_2.html":[],"/2022/08/10/legclf_in_witness_whereof_clause_en_3_2.html":[],"/2022/08/10/legclf_increased_costs_clause_en_3_2.html":[],"/2022/08/10/legclf_indebtedness_clause_en_3_2.html":[],"/2022/08/10/legclf_indemnification_by_the_company_clause_en_3_2.html":[],"/2022/08/10/legclf_indemnification_clause_en_3_2.html":[],"/2022/08/10/legclf_indemnity_clause_en_3_2.html":[],"/2022/08/10/legclf_independent_contractor_clause_en_3_2.html":[],"/2022/08/10/legclf_information_clause_en_3_2.html":[],"/2022/08/10/legclf_injunctive_relief_clause_en_3_2.html":[],"/2022/08/10/legclf_insolvency_clause_en_3_2.html":[],"/2022/08/10/legclf_inspection_clause_en_3_2.html":[],"/2022/08/10/legclf_insurance_clause_en_3_2.html":[],"/2022/08/10/legclf_integration_clause_en_3_2.html":[],"/2022/08/10/legclf_intellectual_property_clause_en_3_2.html":[],"/2022/08/10/legclf_interest_clause_en_3_2.html":[],"/2022/08/10/legclf_interpretation_clause_en_3_2.html":[],"/2022/08/10/legclf_introduction_clause_en_3_2.html":[],"/2022/08/10/legclf_investment_company_clause_en_3_2.html":[],"/2022/08/10/legclf_investments_clause_en_3_2.html":[],"/2022/08/10/legclf_judgments_clause_en_3_2.html":[],"/2022/08/10/legclf_jurisdiction_clause_en_3_2.html":[],"/2022/08/10/legclf_labor_matters_clause_en_3_2.html":[],"/2022/08/10/legclf_laws_clause_en_3_2.html":[],"/2022/08/10/legclf_legal_proceedings_clause_en_3_2.html":[],"/2022/08/10/legclf_legends_clause_en_3_2.html":[],"/2022/08/10/legclf_letters_of_credit_clause_en_3_2.html":[],"/2022/08/10/legclf_liabilities_clause_en_3_2.html":[],"/2022/08/10/legclf_liability_clause_en_3_2.html":[],"/2022/08/10/legclf_licenses_clause_en_3_2.html":[],"/2022/08/10/legclf_liens_clause_en_3_2.html":[],"/2022/08/10/legclf_limitations_clause_en_3_2.html":[],"/2022/08/10/legclf_listing_clause_en_3_2.html":[],"/2022/08/10/legclf_litigation_clause_en_3_2.html":[],"/2022/08/10/legclf_loans_clause_en_3_2.html":[],"/2022/08/10/legclf_maintenance_clause_en_3_2.html":[],"/2022/08/10/legclf_management_clause_en_3_2.html":[],"/2022/08/10/legclf_marketing_clause_en_3_2.html":[],"/2022/08/10/legclf_material_contracts_clause_en_3_2.html":[],"/2022/08/10/legclf_meetings_clause_en_3_2.html":[],"/2022/08/10/legclf_merger_clause_en_3_2.html":[],"/2022/08/10/legclf_miscellaneous_clause_en_3_2.html":[],"/2022/08/10/legclf_modification_and_waiver_clause_en_3_2.html":[],"/2022/08/10/legclf_modifications_clause_en_3_2.html":[],"/2022/08/10/legclf_name_clause_en_3_2.html":[],"/2022/08/10/legclf_negative_covenants_clause_en_3_2.html":[],"/2022/08/10/legclf_no_assignment_clause_en_3_2.html":[],"/2022/08/10/legclf_no_conflicts_clause_en_3_2.html":[],"/2022/08/10/legclf_no_default_clause_en_3_2.html":[],"/2022/08/10/legclf_no_material_adverse_change_clause_en_3_2.html":[],"/2022/08/10/legclf_no_solicitation_clause_en_3_2.html":[],"/2022/08/10/legclf_no_strict_construction_clause_en_3_2.html":[],"/2022/08/10/legclf_no_third_party_beneficiaries_clause_en_3_2.html":[],"/2022/08/10/legclf_no_violation_clause_en_3_2.html":[],"/2022/08/10/legclf_no_waiver_clause_en_3_2.html":[],"/2022/08/10/legclf_non_competition_clause_en_3_2.html":[],"/2022/08/10/legclf_non_discrimination_clause_en_3_2.html":[],"/2022/08/10/legclf_non_disparagement_clause_en_3_2.html":[],"/2022/08/10/legclf_non_solicitation_clause_en_3_2.html":[],"/2022/08/10/legclf_notices_clause_en_3_2.html":[],"/2022/08/10/legclf_notification_clause_en_3_2.html":[],"/2022/08/10/legclf_now_therefore_clause_en_3_2.html":[],"/2022/08/10/legclf_obligations_absolute_clause_en_3_2.html":[],"/2022/08/10/legclf_officers_certificate_clause_en_3_2.html":[],"/2022/08/10/legclf_officers_clause_en_3_2.html":[],"/2022/08/10/legclf_optional_renewal_clause_en_3_2.html":[],"/2022/08/10/legclf_organization_clause_en_3_2.html":[],"/2022/08/10/legclf_other_benefits_clause_en_3_2.html":[],"/2022/08/10/legclf_other_remedies_clause_en_3_2.html":[],"/2022/08/10/legclf_ownership_clause_en_3_2.html":[],"/2022/08/10/legclf_parking_clause_en_3_2.html":[],"/2022/08/10/legclf_partial_invalidity_clause_en_3_2.html":[],"/2022/08/10/legclf_participations_clause_en_3_2.html":[],"/2022/08/10/legclf_parties_clause_en_3_2.html":[],"/2022/08/10/legclf_parties_in_interest_clause_en_3_2.html":[],"/2022/08/10/legclf_payments_clause_en_3_2.html":[],"/2022/08/10/legclf_performance_clause_en_3_2.html":[],"/2022/08/10/legclf_permits_clause_en_3_2.html":[],"/2022/08/10/legclf_persons_clause_en_3_2.html":[],"/2022/08/10/legclf_position_and_duties_clause_en_3_2.html":[],"/2022/08/10/legclf_powers_clause_en_3_2.html":[],"/2022/08/10/legclf_preamble_clause_en_3_2.html":[],"/2022/08/10/legclf_procedures_clause_en_3_2.html":[],"/2022/08/10/legclf_proprietary_rights_clause_en_3_2.html":[],"/2022/08/10/legclf_provisions_clause_en_3_2.html":[],"/2022/08/10/legclf_public_announcements_clause_en_3_2.html":[],"/2022/08/10/legclf_publicity_clause_en_3_2.html":[],"/2022/08/10/legclf_purchase_and_sale_clause_en_3_2.html":[],"/2022/08/10/legclf_purchase_price_clause_en_3_2.html":[],"/2022/08/10/legclf_purpose_clause_en_3_2.html":[],"/2022/08/10/legclf_real_property_clause_en_3_2.html":[],"/2022/08/10/legclf_recitals_clause_en_3_2.html":[],"/2022/08/10/legclf_recognition_clause_en_3_2.html":[],"/2022/08/10/legclf_records_clause_en_3_2.html":[],"/2022/08/10/legclf_redemption_clause_en_3_2.html":[],"/2022/08/10/legclf_registration_clause_en_3_2.html":[],"/2022/08/10/legclf_registration_expenses_clause_en_3_2.html":[],"/2022/08/10/legclf_registration_rights_clause_en_3_2.html":[],"/2022/08/10/legclf_reimbursements_clause_en_3_2.html":[],"/2022/08/10/legclf_reinstatement_clause_en_3_2.html":[],"/2022/08/10/legclf_relationship_of_the_parties_clause_en_3_2.html":[],"/2022/08/10/legclf_release_clause_en_3_2.html":[],"/2022/08/10/legclf_reliance_clause_en_3_2.html":[],"/2022/08/10/legclf_remedies_clause_en_3_2.html":[],"/2022/08/10/legclf_remedies_cumulative_clause_en_3_2.html":[],"/2022/08/10/legclf_rent_clause_en_3_2.html":[],"/2022/08/10/legclf_reporting_clause_en_3_2.html":[],"/2022/08/10/legclf_reports_clause_en_3_2.html":[],"/2022/08/10/legclf_representations_clause_en_3_2.html":[],"/2022/08/10/legclf_resignation_clause_en_3_2.html":[],"/2022/08/10/legclf_restrictions_clause_en_3_2.html":[],"/2022/08/10/legclf_restrictions_on_transfer_clause_en_3_2.html":[],"/2022/08/10/legclf_right_of_setoff_clause_en_3_2.html":[],"/2022/08/10/legclf_rules_of_construction_clause_en_3_2.html":[],"/2022/08/10/legclf_salary_clause_en_3_2.html":[],"/2022/08/10/legclf_scope_clause_en_3_2.html":[],"/2022/08/10/legclf_section_headings_clause_en_3_2.html":[],"/2022/08/10/legclf_security_clause_en_3_2.html":[],"/2022/08/10/legclf_security_interest_clause_en_3_2.html":[],"/2022/08/10/legclf_seniority_clause_en_3_2.html":[],"/2022/08/10/legclf_services_clause_en_3_2.html":[],"/2022/08/10/legclf_set_off_clause_en_3_2.html":[],"/2022/08/10/legclf_severability_clause_en_3_2.html":[],"/2022/08/10/legclf_severance_clause_en_3_2.html":[],"/2022/08/10/legclf_sick_leave_clause_en_3_2.html":[],"/2022/08/10/legclf_solvency_clause_en_3_2.html":[],"/2022/08/10/legclf_special_terms_and_conditions_of_trust_clause_en_3_2.html":[],"/2022/08/10/legclf_specific_performance_clause_en_3_2.html":[],"/2022/08/10/legclf_standard_of_care_clause_en_3_2.html":[],"/2022/08/10/legclf_standard_terms_and_conditions_of_trust_clause_en_3_2.html":[],"/2022/08/10/legclf_stock_options_clause_en_3_2.html":[],"/2022/08/10/legclf_subordination_clause_en_3_2.html":[],"/2022/08/10/legclf_subrogation_clause_en_3_2.html":[],"/2022/08/10/legclf_subsidiaries_clause_en_3_2.html":[],"/2022/08/10/legclf_successors_clause_en_3_2.html":[],"/2022/08/10/legclf_support_clause_en_3_2.html":[],"/2022/08/10/legclf_tax_returns_clause_en_3_2.html":[],"/2022/08/10/legclf_tax_withholding_clause_en_3_2.html":[],"/2022/08/10/legclf_taxes_clause_en_3_2.html":[],"/2022/08/10/legclf_term_and_termination_clause_en_3_2.html":[],"/2022/08/10/legclf_term_of_employment_clause_en_3_2.html":[],"/2022/08/10/legclf_termination_clause_en_3_2.html":[],"/2022/08/10/legclf_termination_of_agreement_clause_en_3_2.html":[],"/2022/08/10/legclf_termination_of_employment_clause_en_3_2.html":[],"/2022/08/10/legclf_terms_clause_en_3_2.html":[],"/2022/08/10/legclf_the_closing_clause_en_3_2.html":[],"/2022/08/10/legclf_the_merger_clause_en_3_2.html":[],"/2022/08/10/legclf_therefore_clause_en_3_2.html":[],"/2022/08/10/legclf_third_party_beneficiaries_clause_en_3_2.html":[],"/2022/08/10/legclf_time_clause_en_3_2.html":[],"/2022/08/10/legclf_title_clause_en_3_2.html":[],"/2022/08/10/legclf_transactions_with_affiliates_clause_en_3_2.html":[],"/2022/08/10/legclf_transfer_clause_en_3_2.html":[],"/2022/08/10/legclf_transfers_clause_en_3_2.html":[],"/2022/08/10/legclf_trustee_may_file_proofs_of_claim_clause_en_3_2.html":[],"/2022/08/10/legclf_undertaking_for_costs_clause_en_3_2.html":[],"/2022/08/10/legclf_usa_patriot_act_clause_en_3_2.html":[],"/2022/08/10/legclf_use_clause_en_3_2.html":[],"/2022/08/10/legclf_use_of_proceeds_clause_en_3_2.html":[],"/2022/08/10/legclf_utilities_clause_en_3_2.html":[],"/2022/08/10/legclf_vacation_clause_en_3_2.html":[],"/2022/08/10/legclf_validity_clause_en_3_2.html":[],"/2022/08/10/legclf_vesting_clause_en_3_2.html":[],"/2022/08/10/legclf_voting_clause_en_3_2.html":[],"/2022/08/10/legclf_waiver_of_jury_trial_clause_en_3_2.html":[],"/2022/08/10/legclf_waivers_clause_en_3_2.html":[],"/2022/08/10/legclf_warranty_clause_en_3_2.html":[],"/2022/08/10/legclf_whereas_clause_en_3_2.html":[],"/2022/08/10/legclf_witnesseth_clause_en_3_2.html":[],"/2022/08/11/bert_token_classifier_negation_uncertainty_es_3_0.html":[],"/2022/08/11/bert_token_classifier_ner_clinical_trials_abstracts_es_3_0.html":[],"/2022/08/12/ner_clinical_trials_abstracts_es_3_0.html":[],"/2022/08/12/legner_bert_grants_en_3_2.html":[],"/2022/08/12/legner_headers_en_3_2.html":[],"/2022/08/12/legner_whereas_en_3_2.html":[],"/2022/08/12/legre_contract_doc_parties_en_3_2.html":[],"/2022/08/13/ner_negation_uncertainty_es_3_0.html":[],"/2022/08/13/ner_pharmacology_es_3_0.html":[],"/2022/08/14/disease_mentions_tweet_es_3_0.html":[],"/2022/08/15/ner_deid_generic_bert_ro_3_0.html":[],"/2022/08/16/finner_arabert_arabic_ar_3_2.html":["https://ontology.birzeit.edu/Wojood/"],"/2022/08/16/legner_contract_doc_parties_en_3_2.html":[],"/2022/08/16/legner_signers_en_3_2.html":[],"/2022/08/17/finassertion_competitors_en_3_2.html":[],"/2022/08/17/finner_10k_summary_en_3_2.html":[],"/2022/08/17/finner_orgs_prods_alias_en_3_2.html":[],"/2022/08/17/finre_org_prod_alias_en_3_2.html":[],"/2022/08/17/legner_orgs_prods_alias_en_3_2.html":[],"/2022/08/17/legre_org_prod_alias_en_3_2.html":[],"/2022/08/18/finmapper_edgar_companyname_en_3_2.html":[],"/2022/08/18/finmapper_edgar_irs_en_3_2.html":[],"/2022/08/18/legmapper_edgar_companyname_en_3_2.html":[],"/2022/08/18/legmapper_edgar_irs_en_3_2.html":[],"/2022/08/22/finre_zero_shot_en_3_2.html":[],"/2022/08/22/legner_obligations_en_3_2.html":[],"/2022/08/22/legre_zero_shot_en_3_2.html":[],"/2022/08/23/drug_ade_mapper_en.html":["https://fis.fda.gov/extensions/FPD-QDE-FAERS/FPD-QDE-FAERS.html"],"/2022/08/24/legpipe_obligations_en.html":[],"/2022/08/24/legpipe_whereas_en.html":[],"/2022/08/24/legre_whereas_en.html":[],"/2022/08/29/finner_headers_en.html":[],"/2022/08/29/zero_shot_ner_roberta_en.html":[],"/2022/08/30/finel_edgar_company_name_en.html":[],"/2022/08/30/finel_edgar_irs_en.html":[],"/2022/08/30/finmulticlf_news_en.html":[],"/2022/08/30/finner_bert_roles_en.html":[],"/2022/08/30/finner_org_per_role_date_en.html":[],"/2022/08/30/legel_edgar_company_name_en.html":[],"/2022/08/30/legel_edgar_irs_en.html":[],"/2022/08/30/legmulticlf_edgar_en.html":["https://metatext.io/datasets/ledgar,"],"/2022/08/31/finner_sec_conll_en.html":[],"/2022/09/02/finner_roberta_zeroshot_en.html":[],"/2022/09/02/legner_roberta_zeroshot_en.html":[],"/2022/09/05/sbertresolve_ner_model_finder_en.html":[],"/2022/09/06/finclf_augmented_esg_en.html":[],"/2022/09/06/finclf_bert_fls_en.html":[],"/2022/09/06/finclf_bert_sentiment_en.html":[],"/2022/09/06/finclf_esg_en.html":[],"/2022/09/07/finclf_bert_sentiment_phrasebank_en.html":[],"/2022/09/07/finvisualclf_vit_tickets_en.html":[],"/2022/09/07/legclf_bert_judgements_agent_en.html":["https://arxiv.org/pdf/2208.06178.pdf"],"/2022/09/07/legclf_bert_judgements_argtype_en.html":["https://arxiv.org/pdf/2208.06178.pdf"],"/2022/09/08/finel_names2tickers_en.html":["https://data.world/johnsnowlabs/list-of-companies-in-nasdaq-exchanges"],"/2022/09/09/finassertiondl_past_roles_en.html":[],"/2022/09/09/finel_tickers2names_en.html":["https://data.world/johnsnowlabs/list-of-companies-in-nasdaq-exchanges"],"/2022/09/09/finpipe_org_per_role_date_en.html":[],"/2022/09/20/legclf_cuad_confidentiality_clause_en.html":[],"/2022/09/20/legclf_cuad_obligations_clause_en.html":[],"/2022/09/20/legclf_cuad_whereas_clause_en.html":[],"/2022/09/21/visualner_10kfilings_en.html":[],"/2022/09/21/visualner_keyvalue_10kfilings_en.html":[],"/2022/09/21/visualner_receipts_xx.html":[],"/2022/09/26/re_oncology_size_wip_en.html":[],"/2022/09/27/finassertion_time_en.html":[],"/2022/09/27/finner_bert_rufacts_ru.html":["https://github.com/dialogue-evaluation/RuREBus"],"/2022/09/27/legassertion_time_en.html":[],"/2022/09/27/legclf_cuad_indemnifications_clause_en.html":[],"/2022/09/27/legclf_cuad_licenses_clause_en.html":[],"/2022/09/27/legner_bert_indemnifications_en.html":[],"/2022/09/27/legner_br_base_pt.html":["https://paperswithcode.com/sotatask=Token+Classification&dataset=lener_br"],"/2022/09/27/legner_br_large_pt.html":["https://paperswithcode.com/sotatask=Token+Classification&dataset=lener_br"],"/2022/09/27/re_oncology_biomarker_result_wip_en.html":[],"/2022/09/27/re_oncology_granular_wip_en.html":[],"/2022/09/27/re_oncology_location_wip_en.html":[],"/2022/09/27/re_oncology_temporal_wip_en.html":[],"/2022/09/27/re_oncology_test_result_wip_en.html":[],"/2022/09/27/re_oncology_wip_en.html":[],"/2022/09/28/finclf_bert_banking77_en.html":["https://paperswithcode.com/dataset/banking77-oos"],"/2022/09/28/finre_work_experience_en.html":[],"/2022/09/28/legclf_enforceability_clause_en.html":[],"/2022/09/28/legclf_enforcement_clause_en.html":[],"/2022/09/28/legclf_environmental_matters_clause_en.html":[],"/2022/09/28/legner_br_bert_base_pt.html":["https://paperswithcode.com/sotatask=Token+Classification&dataset=lener_br"],"/2022/09/28/legner_br_bert_large_pt.html":["https://paperswithcode.com/sotatask=Token+Classification&dataset=lener_br"],"/2022/09/28/legner_law_money_es.html":["https://huggingface.co/datasets/scjnugacj/scjn_dataset_ner","https://huggingface.co/pitoneros/NER_LAW_MONEY4"],"/2022/09/28/legner_laws_treaties_es.html":["https://huggingface.co/datasets/scjnugacj/scjn_dataset_ner","https://www.wipo.int/export/sites/www/pct/es/texts/pdf/pct.pdf)),"],"/2022/09/28/legre_indemnifications_en.html":[],"/2022/09/28/redl_oncology_size_biobert_wip_en.html":[],"/2022/09/29/redl_oncology_biobert_wip_en.html":[],"/2022/09/29/redl_oncology_biomarker_result_biobert_wip_en.html":[],"/2022/09/29/redl_oncology_granular_biobert_wip_en.html":[],"/2022/09/29/redl_oncology_location_biobert_wip_en.html":[],"/2022/09/29/redl_oncology_temporal_biobert_wip_en.html":[],"/2022/09/29/redl_oncology_test_result_biobert_wip_en.html":[],"/2022/09/30/ner_oncology_anatomy_general_wip_en.html":[],"/2022/09/30/ner_oncology_demographics_wip_en.html":[],"/2022/09/30/ner_oncology_diagnosis_wip_en.html":[],"/2022/09/30/ner_oncology_test_wip_en.html":[],"/2022/09/30/ner_oncology_therapy_wip_en.html":[],"/2022/09/30/ner_oncology_tnm_wip_en.html":[],"/2022/09/30/ner_oncology_unspecific_posology_wip_en.html":[],"/2022/09/30/ner_oncology_wip_en.html":[],"/2022/10/01/assertion_oncology_demographic_binary_wip_en.html":[],"/2022/10/01/assertion_oncology_family_history_wip_en.html":[],"/2022/10/01/assertion_oncology_problem_wip_en.html":[],"/2022/10/01/assertion_oncology_response_to_treatment_wip_en.html":[],"/2022/10/01/assertion_oncology_smoking_status_wip_en.html":[],"/2022/10/01/assertion_oncology_test_binary_wip_en.html":[],"/2022/10/01/assertion_oncology_treatment_binary_wip_en.html":[],"/2022/10/01/assertion_oncology_wip_en.html":[],"/2022/10/01/ner_oncology_anatomy_granular_wip_en.html":[],"/2022/10/01/ner_oncology_biomarker_wip_en.html":[],"/2022/10/01/ner_oncology_posology_wip_en.html":[],"/2022/10/01/ner_oncology_response_to_treatment_wip_en.html":[],"/2022/10/02/legner_arabert_arabic_ar.html":["https://ontology.birzeit.edu/Wojood/"],"/2022/10/02/legner_bert_base_courts_de.html":[],"/2022/10/02/legner_bert_large_courts_de.html":[],"/2022/10/02/legner_courts_de.html":[],"/2022/10/11/assertion_oncology_demographic_binary_wip_en.html":[],"/2022/10/11/assertion_oncology_family_history_wip_en.html":[],"/2022/10/11/assertion_oncology_problem_wip_en.html":[],"/2022/10/11/assertion_oncology_response_to_treatment_wip_en.html":[],"/2022/10/11/assertion_oncology_smoking_status_wip_en.html":[],"/2022/10/11/assertion_oncology_treatment_binary_wip_en.html":[],"/2022/10/11/assertion_oncology_wip_en.html":[],"/2022/10/15/finre_has_ticker_en.html":[],"/2022/10/17/legner_confidentiality_en.html":[],"/2022/10/17/legner_warranty_en.html":[],"/2022/10/18/legre_confidentiality_en.html":[],"/2022/10/18/legclf_cuad_warranty_clause_en.html":[],"/2022/10/19/ner_covid_trials_en.html":[],"/2022/10/19/ner_jsl_en.html":["https://www.johnsnowlabs.com/data/"],"/2022/10/19/legre_warranty_en.html":[],"/2022/10/19/finner_financial_medium_en.html":[],"/2022/10/19/finner_financial_small_en.html":[],"/2022/10/20/finner_financial_large_en.html":[],"/2022/10/22/finclf_bert_sentiment_analysis_lt.html":["https://www.kaggle.com/datasets/rokastrimaitis/lithuanian-financial-news-dataset-and-bigramsselect=dataset%28original%29.csv"],"/2022/10/22/finel_nasdaq_data_company_name_en.html":[],"/2022/10/22/finel_nasdaq_data_ticker_en.html":[],"/2022/10/22/finmapper_nasdaq_data_company_name_en.html":[],"/2022/10/22/finmapper_nasdaq_data_ticker_en.html":[],"/2022/10/24/legclf_consulting_agreement_en.html":[],"/2022/10/24/legclf_credit_agreement_en.html":[],"/2022/10/24/legclf_employment_agreement_en.html":[],"/2022/10/24/legclf_lease_agreement_en.html":[],"/2022/10/24/legclf_loan_agreement_en.html":[],"/2022/10/24/legclf_management_contract_en.html":[],"/2022/10/24/legclf_purchase_agreement_en.html":[],"/2022/10/24/legclf_service_agreement_en.html":[],"/2022/10/25/t5_base_pubmedqa_en.html":[],"/2022/10/25/legner_indian_court_judgement_en.html":["https://github.com/Legal-NLP-EkStep/legal_NER3-data"],"/2022/10/25/legner_indian_court_preamble_en.html":["https://github.com/Legal-NLP-EkStep/legal_NER3-data"],"/2022/10/25/finner_sec_10k_summary_en.html":[],"/2022/10/25/ner_oncology_anatomy_general_en.html":[],"/2022/10/25/ner_oncology_anatomy_granular_en.html":[],"/2022/10/25/ner_oncology_biomarker_en.html":[],"/2022/10/25/ner_oncology_demographics_en.html":[],"/2022/10/25/ner_oncology_diagnosis_en.html":[],"/2022/10/25/ner_oncology_en.html":[],"/2022/10/25/ner_oncology_posology_en.html":[],"/2022/10/25/ner_oncology_response_to_treatment_en.html":[],"/2022/10/25/ner_oncology_test_en.html":[],"/2022/10/25/ner_oncology_therapy_en.html":[],"/2022/10/25/ner_oncology_tnm_en.html":[],"/2022/10/25/ner_oncology_unspecific_posology_en.html":[],"/2022/10/27/legclf_bert_swiss_judgements_de.html":["https://zenodo.org/record/7109926.Y1gJwexBw8E"],"/2022/10/27/legclf_bert_swiss_judgements_en.html":["https://zenodo.org/record/7109926.Y1gJwexBw8E"],"/2022/10/27/legclf_bert_swiss_judgements_fr.html":["https://zenodo.org/record/7109926.Y1gJwexBw8E"],"/2022/10/27/legclf_bert_swiss_judgements_it.html":["https://zenodo.org/record/7109926.Y1gJwexBw8E"],"/2022/10/28/sbiobertresolve_icd10pcs_augmented_en.html":["https://www.icd10data.com/ICD10PCS/Codes"],"/2022/11/01/finner_sec_dates_en.html":[],"/2022/11/02/legre_contract_doc_parties_md_en.html":[],"/2022/11/03/legre_obligations_md_en.html":[],"/2022/11/03/finclf_acquisitions_item_en.html":[],"/2022/11/03/finclf_work_experience_item_en.html":[],"/2022/11/04/finclf_auditor_sentiment_analysis_en.html":[],"/2022/11/07/finre_financial_small_en.html":[],"/2022/11/08/finre_acquisitions_subsidiaries_md_en.html":[],"/2022/11/08/finre_work_experience_md_en.html":[],"/2022/11/09/legre_confidentiality_md_en.html":[],"/2022/11/09/legre_grants_md_en.html":[],"/2022/11/09/legre_indemnifications_md_en.html":[],"/2022/11/09/legre_whereas_md_en.html":[],"/2022/11/09/legclf_cuad_termination_clause_en.html":[],"/2022/11/09/legner_termination_en.html":[],"/2022/11/10/legclf_asset_purchase_agreement_en.html":[],"/2022/11/10/legclf_distribution_agreement_en.html":[],"/2022/11/10/legclf_executive_employment_agreement_en.html":[],"/2022/11/10/legclf_indemnification_agreement_en.html":[],"/2022/11/10/legclf_loan_and_security_agreement_en.html":[],"/2022/11/10/legclf_participation_agreement_en.html":[],"/2022/11/10/legclf_securities_purchase_agreement_en.html":[],"/2022/11/10/legclf_security_agreement_en.html":[],"/2022/11/10/legclf_stock_purchase_agreement_en.html":[],"/2022/11/10/legclf_subscription_agreement_en.html":[],"/2022/11/10/legner_romanian_official_lg_ro.html":["https://zenodo.org/record/7025333.Y2zsquxBx83"],"/2022/11/10/legner_romanian_official_md_ro.html":["https://zenodo.org/record/7025333.Y2zsquxBx83"],"/2022/11/10/legner_romanian_official_sm_ro.html":["https://zenodo.org/record/7025333.Y2zsquxBx83"],"/2022/11/10/finclf_indian_news_sentiment_en.html":["https://www.kaggle.com/datasets/harshrkh/india-financial-news-headlines-sentiments"],"/2022/11/10/finclf_indian_news_sentiment_medium_en.html":["https://www.kaggle.com/datasets/harshrkh/india-financial-news-headlines-sentiments"],"/2022/11/10/legclf_contribution_agreement_en.html":[],"/2022/11/10/legclf_custodian_agreement_en.html":[],"/2022/11/10/legclf_exchange_agreement_en.html":[],"/2022/11/10/legclf_general_distribution_agreement_en.html":[],"/2022/11/10/legclf_guarantee_agreement_en.html":[],"/2022/11/10/legclf_intercreditor_agreement_en.html":[],"/2022/11/10/legclf_judgement_de.html":["https://zenodo.org/record/3936490.Y2ybxctBxD-"],"/2022/11/10/legclf_judgement_medium_de.html":["https://zenodo.org/record/3936490.Y2ybxctBxD-"],"/2022/11/10/legclf_master_repurchase_agreement_en.html":[],"/2022/11/10/legclf_pledge_and_security_agreement_en.html":[],"/2022/11/10/legclf_share_exchange_agreement_en.html":[],"/2022/11/10/legclf_terms_agreement_en.html":[],"/2022/11/10/legclf_agreement_and_declaration_en.html":[],"/2022/11/10/legclf_control_agreement_en.html":[],"/2022/11/10/legclf_equity_distribution_agreement_en.html":[],"/2022/11/10/legclf_exclusive_license_agreement_en.html":[],"/2022/11/10/legclf_investment_subadvisory_agreement_en.html":[],"/2022/11/10/legclf_limited_partnership_agreement_en.html":[],"/2022/11/10/legclf_master_lease_agreement_en.html":[],"/2022/11/10/legclf_stockholder_agreement_en.html":[],"/2022/11/10/legclf_sublease_agreement_en.html":[],"/2022/11/10/legclf_transition_services_agreement_en.html":[],"/2022/11/11/legclf_sbert_cuad_termination_clause_en.html":[],"/2022/11/15/ner_sdoh_slim_wip_en.html":["https://mtsamples.com/","https://physionet.org/content/mimiciii/1.4/"],"/2022/11/17/legclf_cuad_signers_clause_en.html":[],"/2022/11/17/legclf_introduction_clause_en.html":[],"/2022/11/21/legclf_dates_sm_en.html":[],"/2022/11/21/legner_dates_sm_en.html":[],"/2022/11/22/ner_deid_generic_bert_ro.html":[],"/2022/11/23/finsum_news_headers_md_en.html":[],"/2022/11/24/ner_oncology_anatomy_general_en.html":[],"/2022/11/24/ner_oncology_anatomy_granular_en.html":[],"/2022/11/24/ner_oncology_biomarker_en.html":[],"/2022/11/24/ner_oncology_demographics_en.html":[],"/2022/11/24/ner_oncology_diagnosis_en.html":[],"/2022/11/24/ner_oncology_en.html":[],"/2022/11/24/ner_oncology_posology_en.html":[],"/2022/11/24/ner_oncology_response_to_treatment_en.html":[],"/2022/11/24/ner_oncology_test_en.html":[],"/2022/11/24/ner_oncology_therapy_en.html":[],"/2022/11/24/ner_oncology_tnm_en.html":[],"/2022/11/24/ner_oncology_unspecific_posology_en.html":[],"/2022/11/24/legclf_administration_agreement_bert_en.html":[],"/2022/11/24/legclf_administration_agreement_en.html":[],"/2022/11/24/legclf_agreement_and_declaration_bert_en.html":[],"/2022/11/24/legclf_asset_purchase_agreement_bert_en.html":[],"/2022/11/24/legclf_consulting_agreement_bert_en.html":[],"/2022/11/24/legclf_contribution_agreement_bert_en.html":[],"/2022/11/24/legclf_control_agreement_bert_en.html":[],"/2022/11/24/legclf_credit_agreement_bert_en.html":[],"/2022/11/24/legclf_custodian_agreement_bert_en.html":[],"/2022/11/24/legclf_distribution_agreement_bert_en.html":[],"/2022/11/24/legclf_employment_agreement_bert_en.html":[],"/2022/11/24/legclf_equity_distribution_agreement_bert_en.html":[],"/2022/11/24/legclf_exchange_agreement_bert_en.html":[],"/2022/11/24/legclf_exclusive_license_agreement_bert_en.html":[],"/2022/11/24/legclf_executive_employment_agreement_bert_en.html":[],"/2022/11/24/legclf_general_distribution_agreement_bert_en.html":[],"/2022/11/24/legclf_guarantee_agreement_bert_en.html":[],"/2022/11/24/legclf_indemnification_agreement_bert_en.html":[],"/2022/11/24/legclf_intercreditor_agreement_bert_en.html":[],"/2022/11/24/legclf_investment_subadvisory_agreement_bert_en.html":[],"/2022/11/24/legclf_joint_filing_agreement_bert_en.html":[],"/2022/11/24/legclf_joint_filing_agreement_en.html":[],"/2022/11/24/legclf_lease_agreement_bert_en.html":[],"/2022/11/24/legclf_letter_agreement_bert_en.html":[],"/2022/11/24/legclf_letter_agreement_en.html":[],"/2022/11/24/legclf_limited_partnership_agreement_bert_en.html":[],"/2022/11/24/legclf_loan_agreement_bert_en.html":[],"/2022/11/24/legclf_note_purchase_agreement_en.html":[],"/2022/11/24/legclf_operating_agreement_en.html":[],"/2022/11/24/legclf_rights_agreement_en.html":[],"/2022/11/24/legclf_separation_agreement_en.html":[],"/2022/11/24/legclf_settlement_agreement_en.html":[],"/2022/11/24/legclf_trust_agreement_en.html":[],"/2022/11/24/legclf_voting_agreement_en.html":[],"/2022/11/24/finclf_earning_broker_10k_en.html":[],"/2022/11/24/finsum_news_headers_lg_en.html":[],"/2022/11/24/finsum_news_md_en.html":[],"/2022/11/25/legclf_loan_and_security_agreement_bert_en.html":[],"/2022/11/25/legclf_management_contract_bert_en.html":[],"/2022/11/25/legclf_master_lease_agreement_bert_en.html":[],"/2022/11/25/legclf_master_repurchase_agreement_bert_en.html":[],"/2022/11/25/legclf_note_purchase_agreement_bert_en.html":[],"/2022/11/25/legclf_operating_agreement_bert_en.html":[],"/2022/11/25/legclf_participation_agreement_bert_en.html":[],"/2022/11/25/legclf_pledge_and_security_agreement_bert_en.html":[],"/2022/11/25/legclf_purchase_agreement_bert_en.html":[],"/2022/11/25/legclf_rights_agreement_bert_en.html":[],"/2022/11/25/legclf_securities_purchase_agreement_bert_en.html":[],"/2022/11/25/legclf_security_agreement_bert_en.html":[],"/2022/11/25/legclf_separation_agreement_bert_en.html":[],"/2022/11/25/legclf_service_agreement_bert_en.html":[],"/2022/11/25/legclf_settlement_agreement_bert_en.html":[],"/2022/11/25/legclf_share_exchange_agreement_bert_en.html":[],"/2022/11/25/legclf_stock_purchase_agreement_bert_en.html":[],"/2022/11/25/legclf_stockholder_agreement_bert_en.html":[],"/2022/11/25/legclf_sublease_agreement_bert_en.html":[],"/2022/11/25/legclf_subscription_agreement_bert_en.html":[],"/2022/11/25/legclf_terms_agreement_bert_en.html":[],"/2022/11/25/legclf_transition_services_agreement_bert_en.html":[],"/2022/11/25/legclf_trust_agreement_bert_en.html":[],"/2022/11/25/legclf_voting_agreement_bert_en.html":[],"/2022/11/25/legclf_additional_covenants_clause_en.html":[],"/2022/11/25/legclf_bulletin_boards_clause_en.html":[],"/2022/11/25/legclf_conversion_clause_en.html":[],"/2022/11/25/legclf_delays_or_omissions_clause_en.html":[],"/2022/11/25/legclf_escrow_clause_en.html":[],"/2022/11/25/legclf_exclusive_remedy_clause_en.html":[],"/2022/11/25/legclf_expenses_indemnity_damage_waiver_clause_en.html":[],"/2022/11/25/legclf_expiration_date_clause_en.html":[],"/2022/11/25/legclf_formation_clause_en.html":[],"/2022/11/25/legclf_hazardous_materials_clause_en.html":[],"/2022/11/25/legclf_indemnification_and_insurance_clause_en.html":[],"/2022/11/25/legclf_leave_of_absence_clause_en.html":[],"/2022/11/25/legclf_limitation_clause_en.html":[],"/2022/11/25/legclf_non_contravention_clause_en.html":[],"/2022/11/25/legclf_ofac_clause_en.html":[],"/2022/11/25/legclf_opinions_of_counsel_clause_en.html":[],"/2022/11/25/legclf_other_definitions_clause_en.html":[],"/2022/11/25/legclf_paid_holidays_clause_en.html":[],"/2022/11/25/legclf_prepayment_clause_en.html":[],"/2022/11/25/legclf_register_clause_en.html":[],"/2022/11/25/legclf_risk_of_loss_clause_en.html":[],"/2022/11/25/legclf_subcontracting_clause_en.html":[],"/2022/11/25/legclf_third_party_rights_clause_en.html":[],"/2022/11/25/legclf_vacancies_clause_en.html":[],"/2022/11/25/legclf_w_i_t_n_e_s_s_e_t_h_clause_en.html":[],"/2022/11/25/legclf_cuad_whereas_clause_en.html":[],"/2022/11/25/legclf_employee_benefit_plans_md_en.html":[],"/2022/11/25/legclf_grievance_procedure_md_en.html":[],"/2022/11/25/legclf_indemnification_and_contribution_md_en.html":[],"/2022/11/25/legclf_indemnification_md_en.html":[],"/2022/11/25/legclf_introduction_clause_cuad_en.html":[],"/2022/11/25/legclf_method_of_payment_md_en.html":[],"/2022/11/25/legclf_power_of_attorney_md_en.html":[],"/2022/11/25/legclf_termination_md_en.html":[],"/2022/11/25/legclf_whereas_md_en.html":[],"/2022/11/28/finre_earning_calls_sm_en.html":[],"/2022/11/28/legclf_cuad_confidentiality_clause_en.html":[],"/2022/11/28/legclf_cuad_obligations_clause_en.html":[],"/2022/11/30/legner_ronec_ro.html":["https://github.com/dumitrescustefan/ronec"],"/2022/11/30/finner_earning_calls_generic_sm_en.html":[],"/2022/11/30/finner_earning_calls_specific_sm_en.html":[],"/2022/11/30/finner_financial_xlarge_en.html":[],"/2022/11/30/finner_german_financial_entities_de.html":["https://huggingface.co/datasets/fabianrausch/financial-entities-values-augmented"],"/2022/11/30/legclf_cuad_force_majeure_clause_en.html":[],"/2022/11/30/legner_force_majeure_en.html":[],"/2022/12/01/finclf_sec_filings_en.html":[],"/2022/12/01/legner_contract_doc_parties_md_en.html":[],"/2022/12/01/legner_grants_md_en.html":[],"/2022/12/01/legner_indemnifications_md_en.html":[],"/2022/12/01/legner_termination_md_en.html":[],"/2022/12/01/legner_warranty_md_en.html":[],"/2022/12/01/legner_whereas_md_en.html":[],"/2022/12/02/finner_10q_xbrl_en.html":["https://huggingface.co/datasets/nlpaueb/finer-139,"],"/2022/12/05/legclf_eminent_domain_clause_en.html":[],"/2022/12/05/legclf_erisa_reports_clause_en.html":[],"/2022/12/05/legclf_injury_pay_clause_en.html":[],"/2022/12/05/legclf_no_appraisal_rights_clause_en.html":[],"/2022/12/05/legclf_payment_of_interest_defaulted_interest_clause_en.html":[],"/2022/12/05/legclf_principal_underwriter_clause_en.html":[],"/2022/12/05/legclf_retention_of_sub_adviser_clause_en.html":[],"/2022/12/05/legclf_right_to_cure_clause_en.html":[],"/2022/12/05/legclf_sick_days_clause_en.html":[],"/2022/12/05/legclf_successor_to_the_bank_clause_en.html":[],"/2022/12/06/legclf_agreement_and_plan_of_reorganization_bert_en.html":[],"/2022/12/06/legclf_agreement_and_plan_of_reorganization_en.html":[],"/2022/12/06/legclf_deposit_agreement_bert_en.html":[],"/2022/12/06/legclf_deposit_agreement_en.html":[],"/2022/12/06/legclf_indemnity_agreement_bert_en.html":[],"/2022/12/06/legclf_indemnity_agreement_en.html":[],"/2022/12/06/legclf_investment_advisory_agreement_bert_en.html":[],"/2022/12/06/legclf_investment_advisory_agreement_en.html":[],"/2022/12/06/legclf_option_agreement_bert_en.html":[],"/2022/12/06/legclf_option_agreement_en.html":[],"/2022/12/06/legclf_pledge_agreement_bert_en.html":[],"/2022/12/06/legclf_pledge_agreement_en.html":[],"/2022/12/06/legclf_restricted_stock_unit_agreement_bert_en.html":[],"/2022/12/06/legclf_restricted_stock_unit_agreement_en.html":[],"/2022/12/06/legclf_revolving_credit_agreement_bert_en.html":[],"/2022/12/06/legclf_revolving_credit_agreement_en.html":[],"/2022/12/06/legclf_severance_agreement_bert_en.html":[],"/2022/12/06/legclf_severance_agreement_en.html":[],"/2022/12/06/legclf_underwriting_agreement_bert_en.html":[],"/2022/12/06/legclf_underwriting_agreement_en.html":[],"/2022/12/07/legclf_business_day_clause_en.html":[],"/2022/12/07/legclf_demand_registration_clause_en.html":[],"/2022/12/07/legclf_electronic_communications_clause_en.html":[],"/2022/12/07/legclf_entire_agreement_clause_en.html":[],"/2022/12/07/legclf_governing_law_clause_en.html":[],"/2022/12/07/legclf_health_and_safety_clause_en.html":[],"/2022/12/07/legclf_language_clause_en.html":[],"/2022/12/07/legclf_replacement_of_lenders_clause_en.html":[],"/2022/12/07/legclf_rules_and_regulations_clause_en.html":[],"/2022/12/07/legclf_ti_allowance_clause_en.html":[],"/2022/12/09/legclf_administrative_services_agreement_bert_en.html":[],"/2022/12/09/legclf_administrative_services_agreement_en.html":[],"/2022/12/09/legclf_aircraft_lease_agreement_bert_en.html":[],"/2022/12/09/legclf_aircraft_lease_agreement_en.html":[],"/2022/12/09/legclf_custody_agreement_bert_en.html":[],"/2022/12/09/legclf_custody_agreement_en.html":[],"/2022/12/09/legclf_expense_limitation_agreement_bert_en.html":[],"/2022/12/09/legclf_expense_limitation_agreement_en.html":[],"/2022/12/09/legclf_joinder_agreement_bert_en.html":[],"/2022/12/09/legclf_joinder_agreement_en.html":[],"/2022/12/09/legclf_plan_and_agreement_of_merger_bert_en.html":[],"/2022/12/09/legclf_plan_and_agreement_of_merger_en.html":[],"/2022/12/09/legclf_reference_trust_agreement_bert_en.html":[],"/2022/12/09/legclf_reference_trust_agreement_en.html":[],"/2022/12/09/legclf_restricted_stock_agreement_bert_en.html":[],"/2022/12/09/legclf_restricted_stock_agreement_en.html":[],"/2022/12/09/legclf_share_purchase_agreement_bert_en.html":[],"/2022/12/09/legclf_share_purchase_agreement_en.html":[],"/2022/12/09/legclf_subadvisory_agreement_bert_en.html":[],"/2022/12/09/legclf_subadvisory_agreement_en.html":[],"/2022/12/14/finner_10q_xbrl_md_subset1_en.html":["https://huggingface.co/datasets/nlpaueb/finer-139,"],"/2022/12/14/finner_10q_xbrl_md_subset2_en.html":["https://huggingface.co/datasets/nlpaueb/finer-139,"],"/2022/12/14/finner_10q_xbrl_md_subset3_en.html":["https://huggingface.co/datasets/nlpaueb/finer-139,"],"/2022/12/15/finner_contraliability_en.html":[],"/2022/12/15/finner_earning_calls_generic_md_en.html":[],"/2022/12/15/finner_earning_calls_specific_md_en.html":[],"/2022/12/15/finner_10q_xbrl_md_subset12_en.html":["https://huggingface.co/datasets/nlpaueb/finer-139,"],"/2022/12/15/finner_10q_xbrl_md_subset5_en.html":["https://huggingface.co/datasets/nlpaueb/finer-139,"],"/2022/12/15/finner_10q_xlbr_md_subset10_en.html":["https://huggingface.co/datasets/nlpaueb/finer-139,"],"/2022/12/15/finner_10q_xlbr_md_subset11_en.html":["https://huggingface.co/datasets/nlpaueb/finer-139,"],"/2022/12/15/finner_10q_xlbr_md_subset4_en.html":["https://huggingface.co/datasets/nlpaueb/finer-139,"],"/2022/12/15/finner_10q_xlbr_md_subset6_en.html":["https://huggingface.co/datasets/nlpaueb/finer-139,"],"/2022/12/15/finner_10q_xlbr_md_subset7_en.html":["https://huggingface.co/datasets/nlpaueb/finer-139,"],"/2022/12/15/finner_10q_xlbr_md_subset8_en.html":["https://huggingface.co/datasets/nlpaueb/finer-139,"],"/2022/12/15/finner_10q_xlbr_md_subset9_en.html":["https://huggingface.co/datasets/nlpaueb/finer-139,"],"/2022/12/16/legclf_notice_clause_en.html":[],"/2022/12/16/legner_notice_clause_en.html":[],"/2022/12/16/legassertion_sigma_absa_sentiment_en.html":["https://metatext.io/datasets/sigmalaw-absa"],"/2022/12/16/legner_sigma_absa_people_en.html":["https://metatext.io/datasets/sigmalaw-absa"],"/2022/12/17/legre_notice_clause_xs_en.html":[],"/2022/12/18/meddroprof_scielowiki_es.html":["https://temu.bsc.es/meddoprof/data/"],"/2022/12/18/legclf_agreement_bert_en.html":[],"/2022/12/18/legclf_agreement_en.html":[],"/2022/12/18/legclf_applicable_law_clause_en.html":[],"/2022/12/18/legclf_confidential_information_clause_en.html":[],"/2022/12/18/legclf_defined_terms_clause_en.html":[],"/2022/12/18/legclf_events_of_default_clause_en.html":[],"/2022/12/18/legclf_general_provisions_clause_en.html":[],"/2022/12/18/legclf_indenture_agreement_bert_en.html":[],"/2022/12/18/legclf_indenture_agreement_en.html":[],"/2022/12/18/legclf_license_agreement_bert_en.html":[],"/2022/12/18/legclf_license_agreement_en.html":[],"/2022/12/18/legclf_limitation_of_liability_clause_en.html":[],"/2022/12/18/legclf_limited_liability_company_agreement_bert_en.html":[],"/2022/12/18/legclf_limited_liability_company_agreement_en.html":[],"/2022/12/18/legclf_management_agreement_bert_en.html":[],"/2022/12/18/legclf_management_agreement_en.html":[],"/2022/12/18/legclf_registration_rights_agreement_bert_en.html":[],"/2022/12/18/legclf_registration_rights_agreement_en.html":[],"/2022/12/18/legclf_representations_and_warranties_clause_en.html":[],"/2022/12/18/legclf_representations_and_warranties_of_the_company_clause_en.html":[],"/2022/12/18/legclf_stock_option_agreement_bert_en.html":[],"/2022/12/18/legclf_stock_option_agreement_en.html":[],"/2022/12/18/legclf_sub_advisory_agreement_bert_en.html":[],"/2022/12/18/legclf_sub_advisory_agreement_en.html":[],"/2022/12/18/legclf_successors_and_assigns_clause_en.html":[],"/2022/12/18/legclf_supplemental_indenture_agreement_bert_en.html":[],"/2022/12/18/legclf_supplemental_indenture_agreement_en.html":[],"/2022/12/18/legclf_survival_clause_en.html":[],"/2022/12/18/legclf_warrant_agreement_bert_en.html":[],"/2022/12/18/legclf_warrant_agreement_en.html":[],"/2023/01/01/finassertion_negation_en.html":[],"/2023/01/01/legassertion_negation_en.html":[],"/2023/01/01/legner_org_per_role_date_en.html":[],"/2023/01/02/finner_10q_xbrl_lg_asset_en.html":["https://huggingface.co/datasets/nlpaueb/finer-139,"],"/2023/01/02/finner_10q_xbrl_lg_contra_liability_en.html":["https://huggingface.co/datasets/nlpaueb/finer-139,"],"/2023/01/02/finner_10q_xbrl_lg_contra_stock_equity_en.html":["https://huggingface.co/datasets/nlpaueb/finer-139,"],"/2023/01/02/finner_10q_xbrl_lg_debt_en.html":["https://huggingface.co/datasets/nlpaueb/finer-139,"],"/2023/01/02/finner_10q_xbrl_lg_expense_en.html":["https://huggingface.co/datasets/nlpaueb/finer-139,"],"/2023/01/02/finner_10q_xbrl_lg_income_en.html":["https://huggingface.co/datasets/nlpaueb/finer-139,"],"/2023/01/02/finner_10q_xbrl_lg_liability_en.html":["https://huggingface.co/datasets/nlpaueb/finer-139,"],"/2023/01/02/finner_10q_xbrl_lg_revenue_en.html":["https://huggingface.co/datasets/nlpaueb/finer-139,"],"/2023/01/02/legassertion_time_md_en.html":[],"/2023/01/02/legner_roles_en.html":[],"/2023/01/03/finqa_bert_en.html":[],"/2023/01/03/finqa_bert_large_en.html":[],"/2023/01/04/finassertiondl_time_md_en.html":[],"/2023/01/10/visualner_10kfilings_en_3_2.html":[],"/2023/01/10/visualner_keyvalue_10kfilings_en_3_2.html":[],"/2023/01/11/ner_oncology_anatomy_general_healthcare_en.html":[],"/2023/01/11/ner_oncology_biomarker_healthcare_en.html":[],"/2023/01/11/ner_oncology_unspecific_posology_healthcare_en.html":[],"/2023/01/11/legclf_affirmative_covenants_md_en.html":[],"/2023/01/11/legclf_amendments_and_waivers_md_en.html":[],"/2023/01/11/legclf_attorney_fees_md_en.html":[],"/2023/01/11/legclf_choice_of_law_md_en.html":[],"/2023/01/11/legclf_conditions_precedent_md_en.html":[],"/2023/01/11/legclf_effect_of_termination_md_en.html":[],"/2023/01/11/legclf_fees_and_expenses_md_en.html":[],"/2023/01/11/legclf_miscellaneous_provisions_md_en.html":[],"/2023/01/11/legclf_tax_matters_md_en.html":[],"/2023/01/11/legclf_term_of_agreement_md_en.html":[],"/2023/01/11/legclf_termination_for_cause_md_en.html":[],"/2023/01/12/legclf_applicable_law_cuad_en.html":[],"/2023/01/12/legner_applicable_law_clause_en.html":[],"/2023/01/13/finclf_sec_schedules_filings_en.html":[],"/2023/01/13/finmapper_wikipedia_parentcompanies_en.html":[],"/2023/01/13/finmapper_wikipedia_parentcompanies_ticker_en.html":[],"/2023/01/14/redl_ade_biobert_en.html":[],"/2023/01/14/redl_bodypart_direction_biobert_en.html":[],"/2023/01/14/redl_bodypart_problem_biobert_en.html":[],"/2023/01/14/redl_bodypart_procedure_test_biobert_en.html":[],"/2023/01/14/redl_chemprot_biobert_en.html":[],"/2023/01/14/redl_clinical_biobert_en.html":[],"/2023/01/14/redl_date_clinical_biobert_en.html":[],"/2023/01/14/redl_drug_drug_interaction_biobert_en.html":[],"/2023/01/14/redl_drugprot_biobert_en.html":[],"/2023/01/14/redl_human_phenotype_gene_biobert_en.html":[],"/2023/01/15/redl_nihss_biobert_en.html":[],"/2023/01/15/redl_oncology_biobert_wip_en.html":[],"/2023/01/15/redl_oncology_biomarker_result_biobert_wip_en.html":[],"/2023/01/15/redl_oncology_granular_biobert_wip_en.html":[],"/2023/01/15/redl_oncology_location_biobert_wip_en.html":[],"/2023/01/15/redl_oncology_size_biobert_wip_en.html":[],"/2023/01/15/redl_oncology_temporal_biobert_wip_en.html":[],"/2023/01/15/redl_oncology_test_result_biobert_wip_en.html":[],"/2023/01/15/redl_temporal_events_biobert_en.html":[],"/2023/01/15/finner_wiki_formername_en.html":[],"/2023/01/15/finner_wiki_founding_dates_en.html":[],"/2023/01/15/finner_wiki_nationality_en.html":[],"/2023/01/15/finner_wiki_sector_en.html":[],"/2023/01/15/finner_wiki_stockexchange_en.html":[],"/2023/01/18/finel_wiki_parentorgs_en.html":[],"/2023/01/18/finel_wiki_parentorgs_ticker_en.html":[],"/2023/01/18/legclf_dispute_clauses_cuad_en.html":[],"/2023/01/18/legner_dispute_clauses_en.html":[],"/2023/01/19/finmapper_nasdaq_company_name_stock_screener_en.html":["https://www.nasdaq.com/market-activity/stocks/screener"],"/2023/01/19/finmapper_nasdaq_ticker_stock_screener_en.html":["https://www.nasdaq.com/market-activity/stocks/screener"],"/2023/01/20/finel_nasdaq_company_name_stock_screener_en.html":["https://www.nasdaq.com/market-activity/stocks/screener"],"/2023/01/20/finel_nasdaq_ticker_stock_screener_en.html":["https://www.nasdaq.com/market-activity/stocks/screener"],"/2023/01/21/legner_contract_doc_parties_lg_en.html":[],"/2023/01/25/ner_eu_clinical_case_en.html":[],"/2023/01/26/legclf_agreement_of_purchase_and_sale_bert_en.html":[],"/2023/01/26/legclf_confidential_treatment_bert_en.html":[],"/2023/01/26/legclf_form_of_indemnification_agreement_bert_en.html":[],"/2023/01/26/legclf_independent_contractor_agreement_bert_en.html":[],"/2023/01/26/legclf_non_competition_agreement_bert_en.html":[],"/2023/01/26/legclf_principal_underwriting_agreement_bert_en.html":[],"/2023/01/26/legclf_settlement_agreement_and_mutual_release_bert_en.html":[],"/2023/01/26/legclf_shareholder_services_agreement_bert_en.html":[],"/2023/01/26/legclf_term_loan_credit_agreement_bert_en.html":[],"/2023/01/26/legclf_trademark_license_agreement_bert_en.html":[],"/2023/01/27/legclf_absence_of_litigation_clause_en.html":[],"/2023/01/27/legclf_application_of_trust_money_clause_en.html":[],"/2023/01/27/legclf_benefits_of_indenture_clause_en.html":[],"/2023/01/27/legclf_capital_expenditures_clause_en.html":[],"/2023/01/27/legclf_deposit_of_redemption_price_clause_en.html":[],"/2023/01/27/legclf_disclosure_of_information_clause_en.html":[],"/2023/01/27/legclf_indemnification_procedures_clause_en.html":[],"/2023/01/27/legclf_method_of_exercise_clause_en.html":[],"/2023/01/27/legclf_satisfaction_and_discharge_of_indenture_clause_en.html":[],"/2023/01/27/legclf_termination_for_convenience_clause_en.html":[],"/2023/01/29/legclf_adoption_agreement_bert_en.html":[],"/2023/01/29/legclf_annual_bonus_clause_en.html":[],"/2023/01/29/legclf_arrangement_agreement_bert_en.html":[],"/2023/01/29/legclf_assignment_and_subletting_clause_en.html":[],"/2023/01/29/legclf_board_of_directors_clause_en.html":[],"/2023/01/29/legclf_business_expenses_clause_en.html":[],"/2023/01/29/legclf_compensation_agreement_bert_en.html":[],"/2023/01/29/legclf_conditions_of_underwriters_obligations_clause_en.html":[],"/2023/01/29/legclf_cusip_numbers_clause_en.html":[],"/2023/01/29/legclf_due_authorization_clause_en.html":[],"/2023/01/29/legclf_fringe_benefits_clause_en.html":[],"/2023/01/29/legclf_investment_advisory_and_management_agreement_bert_en.html":[],"/2023/01/29/legclf_maintenance_of_insurance_clause_en.html":[],"/2023/01/29/legclf_master_administrative_services_agreement_bert_en.html":[],"/2023/01/29/legclf_military_leave_clause_en.html":[],"/2023/01/29/legclf_no_material_adverse_effect_clause_en.html":[],"/2023/01/29/legclf_non_exclusivity_clause_en.html":[],"/2023/01/29/legclf_noncompetition_agreement_bert_en.html":[],"/2023/01/29/legclf_other_definitional_provisions_clause_en.html":[],"/2023/01/29/legclf_performance_share_award_agreement_bert_en.html":[],"/2023/01/29/legclf_quiet_enjoyment_clause_en.html":[],"/2023/01/29/legclf_reimbursement_of_expenses_clause_en.html":[],"/2023/01/29/legclf_retirement_agreement_bert_en.html":[],"/2023/01/29/legclf_right_of_first_refusal_clause_en.html":[],"/2023/01/29/legclf_standstill_agreement_bert_en.html":[],"/2023/01/29/legclf_subcontractors_clause_en.html":[],"/2023/01/29/legclf_sublicense_agreement_bert_en.html":[],"/2023/01/29/legclf_titles_and_subtitles_clause_en.html":[],"/2023/01/29/legclf_waiver_of_subrogation_clause_en.html":[],"/2023/01/30/legner_roberta_zeroshot_cuad_base_en.html":[],"/2023/01/30/legner_roberta_zeroshot_cuad_large_en.html":[],"/2023/01/30/legner_roberta_zeroshot_cuad_small_en.html":[],"/2023/01/30/legqa_roberta_cuad_base_en.html":[],"/2023/01/30/legqa_roberta_cuad_large_en.html":[],"/2023/01/30/legqa_roberta_cuad_small_en.html":[],"/2023/01/31/finclf_bert_broker_recommendation_en.html":[],"/2023/01/31/finclf_bert_broker_sentiment_analysis_en.html":[],"/2023/01/31/legclf_bert_maud_en.html":[],"/2023/02/01/ner_eu_clinical_case_es.html":[],"/2023/02/01/ner_eu_clinical_case_fr.html":[],"/2023/02/01/finner_capital_calls_en.html":[],"/2023/02/02/legclf_acquisition_agreement_bert_en.html":[],"/2023/02/02/legclf_forbearance_agreement_bert_en.html":[],"/2023/02/02/legclf_limited_liability_company_operating_agreement_bert_en.html":[],"/2023/02/02/legclf_nonstatutory_stock_option_agreement_bert_en.html":[],"/2023/02/02/legclf_private_placement_warrants_purchase_agreement_bert_en.html":[],"/2023/02/02/legclf_sales_agreement_bert_en.html":[],"/2023/02/02/legclf_second_supplemental_indenture_bert_en.html":[],"/2023/02/02/legclf_stock_pledge_agreement_bert_en.html":[],"/2023/02/02/legclf_subordination_agreement_bert_en.html":[],"/2023/02/02/legclf_third_supplemental_indenture_bert_en.html":[],"/2023/02/02/ner_eu_clinical_case_eu.html":[],"/2023/02/02/legmulticlf_mnda_sections_en.html":[],"/2023/02/03/finclf_customer_service_category_en.html":["https://github.com/bitext/customer-support-intent-detection-evaluation-dataset"],"/2023/02/03/finclf_customer_service_intent_type_en.html":["https://github.com/bitext/customer-support-intent-detection-evaluation-dataset"],"/2023/02/03/finmulticlf_customer_service_lin_features_en.html":["https://github.com/bitext/customer-support-intent-detection-training-dataset"],"/2023/02/04/finner_finance_chinese_sm_zh.html":["https://aclanthology.org/D19-1032"],"/2023/02/06/ner_eu_clinical_condition_en.html":[],"/2023/02/06/ner_eu_clinical_condition_es.html":[],"/2023/02/06/ner_eu_clinical_condition_eu.html":[],"/2023/02/06/ner_eu_clinical_condition_fr.html":[],"/2023/02/06/ner_eu_clinical_condition_it.html":[],"/2023/02/08/legclf_commercial_lease_en.html":[],"/2023/02/08/legclf_nda_agreements_en.html":[],"/2023/02/09/legmulticlf_mnda_sections_other_en.html":[],"/2023/02/13/legclf_applic_law_clause_en.html":[],"/2023/02/13/legclf_assignment_clause_en.html":[],"/2023/02/13/legclf_def_of_conf_info_clause_en.html":[],"/2023/02/13/legclf_dispute_resol_clause_en.html":[],"/2023/02/13/legclf_exceptions_clause_en.html":[],"/2023/02/13/legclf_names_of_parties_clause_en.html":[],"/2023/02/13/legclf_non_comp_clause_en.html":[],"/2023/02/13/legclf_non_solic_clause_en.html":[],"/2023/02/13/legclf_permitted_use_clause_en.html":[],"/2023/02/13/legclf_preamble_clause_en.html":[],"/2023/02/13/legclf_remedies_clause_en.html":[],"/2023/02/13/legclf_req_discl_clause_en.html":[],"/2023/02/13/legclf_restricted_use_clause_en.html":[],"/2023/02/13/legclf_return_of_conf_info_clause_en.html":[],"/2023/02/13/legclf_termination_clause_en.html":[],"/2023/02/16/finclf_capital_call_notices_en.html":[],"/2023/02/16/legsum_proposal_en.html":["https://touche.webis.de/clef23/touche23-web/multilingual-stance-classification.htmldata"],"/2023/02/16/finclf_bert_broker_reports_suggested_actions_en.html":[],"/2023/02/17/legclf_bert_support_proposal_en.html":["https://touche.webis.de/clef23/touche23-web/multilingual-stance-classification.htmldata"],"/2023/02/17/legclf_proposal_topic_en.html":["https://touche.webis.de/clef23/touche23-web/multilingual-stance-classification.htmldata"],"/2023/02/22/sbiobertresolve_rxnorm_nih_en.html":["https://www.nlm.nih.gov/research/umls/rxnorm/docs/rxnormfiles.html"],"/2023/02/23/rxnorm_nih_mapper_en.html":["https://www.nlm.nih.gov/research/umls/rxnorm/docs/rxnormfiles.html"],"/2023/02/24/finner_deid_sec_en.html":[],"/2023/02/24/finner_signers_en.html":[],"/2023/03/03/finclf_bert_news_tweets_sentiment_analysis_en.html":[],"/2023/03/03/legner_definitions_en.html":[],"/2023/03/04/finsum_us_news_headers_en.html":["https://www.kaggle.com/datasets/jeet2016/us-financial-news-articles"],"/2023/03/05/legclf_adjustments_bert_en.html":["https://huggingface.co/datasets/lex_glue"],"/2023/03/05/legclf_agreements_bert_en.html":["https://huggingface.co/datasets/lex_glue"],"/2023/03/05/legclf_amendments_bert_en.html":["https://huggingface.co/datasets/lex_glue"],"/2023/03/05/legclf_anti_corruption_laws_bert_en.html":["https://huggingface.co/datasets/lex_glue"],"/2023/03/05/legclf_applicable_laws_bert_en.html":["https://huggingface.co/datasets/lex_glue"],"/2023/03/05/legclf_approvals_bert_en.html":["https://huggingface.co/datasets/lex_glue"],"/2023/03/05/legclf_arbitration_bert_en.html":["https://huggingface.co/datasets/lex_glue"],"/2023/03/05/legclf_assignments_bert_en.html":["https://huggingface.co/datasets/lex_glue"],"/2023/03/05/legclf_assigns_bert_en.html":["https://huggingface.co/datasets/lex_glue"],"/2023/03/05/legclf_authority_bert_en.html":["https://huggingface.co/datasets/lex_glue"],"/2023/03/05/legclf_authorizations_bert_en.html":["https://huggingface.co/datasets/lex_glue"],"/2023/03/05/legclf_base_salary_bert_en.html":["https://huggingface.co/datasets/lex_glue"],"/2023/03/05/legclf_benefits_bert_en.html":["https://huggingface.co/datasets/lex_glue"],"/2023/03/05/legclf_binding_effects_bert_en.html":["https://huggingface.co/datasets/lex_glue"],"/2023/03/05/legclf_brokers_bert_en.html":["https://huggingface.co/datasets/lex_glue"],"/2023/03/05/legclf_capitalization_bert_en.html":["https://huggingface.co/datasets/lex_glue"],"/2023/03/05/legclf_change_in_control_bert_en.html":["https://huggingface.co/datasets/lex_glue"],"/2023/03/05/legclf_closings_bert_en.html":["https://huggingface.co/datasets/lex_glue"],"/2023/03/05/legclf_compliance_with_laws_bert_en.html":["https://huggingface.co/datasets/lex_glue"],"/2023/03/05/legclf_confidentiality_bert_en.html":["https://huggingface.co/datasets/lex_glue"],"/2023/03/05/legclf_consent_to_jurisdiction_bert_en.html":["https://huggingface.co/datasets/lex_glue"],"/2023/03/05/legclf_consents_bert_en.html":["https://huggingface.co/datasets/lex_glue"],"/2023/03/05/legclf_construction_bert_en.html":["https://huggingface.co/datasets/lex_glue"],"/2023/03/05/legclf_cooperation_bert_en.html":["https://huggingface.co/datasets/lex_glue"],"/2023/03/05/legclf_costs_bert_en.html":["https://huggingface.co/datasets/lex_glue"],"/2023/03/05/legclf_counterparts_bert_en.html":["https://huggingface.co/datasets/lex_glue"],"/2023/03/05/legclf_death_bert_en.html":["https://huggingface.co/datasets/lex_glue"],"/2023/03/05/legclf_defined_terms_bert_en.html":["https://huggingface.co/datasets/lex_glue"],"/2023/03/05/legclf_definitions_bert_en.html":["https://huggingface.co/datasets/lex_glue"],"/2023/03/05/legclf_disability_bert_en.html":["https://huggingface.co/datasets/lex_glue"],"/2023/03/05/legclf_disclosures_bert_en.html":["https://huggingface.co/datasets/lex_glue"],"/2023/03/05/legclf_duties_bert_en.html":["https://huggingface.co/datasets/lex_glue"],"/2023/03/05/legclf_effective_dates_bert_en.html":["https://huggingface.co/datasets/lex_glue"],"/2023/03/05/legclf_effectiveness_bert_en.html":["https://huggingface.co/datasets/lex_glue"],"/2023/03/05/legclf_employment_bert_en.html":["https://huggingface.co/datasets/lex_glue"],"/2023/03/05/legclf_enforceability_bert_en.html":["https://huggingface.co/datasets/lex_glue"],"/2023/03/05/legclf_enforcements_bert_en.html":["https://huggingface.co/datasets/lex_glue"],"/2023/03/05/legclf_entire_agreements_bert_en.html":["https://huggingface.co/datasets/lex_glue"],"/2023/03/05/legclf_erisa_bert_en.html":["https://huggingface.co/datasets/lex_glue"],"/2023/03/05/legclf_existence_bert_en.html":["https://huggingface.co/datasets/lex_glue"],"/2023/03/05/legclf_expenses_bert_en.html":["https://huggingface.co/datasets/lex_glue"],"/2023/03/05/legclf_fees_bert_en.html":["https://huggingface.co/datasets/lex_glue"],"/2023/03/05/legclf_financial_statements_bert_en.html":["https://huggingface.co/datasets/lex_glue"],"/2023/03/05/legclf_forfeitures_bert_en.html":["https://huggingface.co/datasets/lex_glue"],"/2023/03/05/legclf_further_assurances_bert_en.html":["https://huggingface.co/datasets/lex_glue"],"/2023/03/05/legclf_general_bert_en.html":["https://huggingface.co/datasets/lex_glue"],"/2023/03/05/legclf_governing_laws_bert_en.html":["https://huggingface.co/datasets/lex_glue"],"/2023/03/05/legclf_headings_bert_en.html":["https://huggingface.co/datasets/lex_glue"],"/2023/03/05/legclf_indemnifications_bert_en.html":["https://huggingface.co/datasets/lex_glue"],"/2023/03/05/legclf_indemnity_bert_en.html":["https://huggingface.co/datasets/lex_glue"],"/2023/03/05/legclf_insurances_bert_en.html":["https://huggingface.co/datasets/lex_glue"],"/2023/03/05/legclf_integration_bert_en.html":["https://huggingface.co/datasets/lex_glue"],"/2023/03/05/legclf_intellectual_property_bert_en.html":["https://huggingface.co/datasets/lex_glue"],"/2023/03/05/legclf_interests_bert_en.html":["https://huggingface.co/datasets/lex_glue"],"/2023/03/05/legclf_interpretations_bert_en.html":["https://huggingface.co/datasets/lex_glue"],"/2023/03/05/legclf_jurisdictions_bert_en.html":["https://huggingface.co/datasets/lex_glue"],"/2023/03/05/legclf_liens_bert_en.html":["https://huggingface.co/datasets/lex_glue"],"/2023/03/05/legclf_litigations_bert_en.html":["https://huggingface.co/datasets/lex_glue"],"/2023/03/05/legclf_miscellaneous_bert_en.html":["https://huggingface.co/datasets/lex_glue"],"/2023/03/05/legclf_modifications_bert_en.html":["https://huggingface.co/datasets/lex_glue"],"/2023/03/05/legclf_no_conflicts_bert_en.html":["https://huggingface.co/datasets/lex_glue"],"/2023/03/05/legclf_no_defaults_bert_en.html":["https://huggingface.co/datasets/lex_glue"],"/2023/03/05/legclf_no_waivers_bert_en.html":["https://huggingface.co/datasets/lex_glue"],"/2023/03/05/legclf_non_disparagement_bert_en.html":["https://huggingface.co/datasets/lex_glue"],"/2023/03/05/legclf_notices_bert_en.html":["https://huggingface.co/datasets/lex_glue"],"/2023/03/05/legclf_organizations_bert_en.html":["https://huggingface.co/datasets/lex_glue"],"/2023/03/05/legclf_participations_bert_en.html":["https://huggingface.co/datasets/lex_glue"],"/2023/03/05/legclf_payments_bert_en.html":["https://huggingface.co/datasets/lex_glue"],"/2023/03/05/legclf_positions_bert_en.html":["https://huggingface.co/datasets/lex_glue"],"/2023/03/05/legclf_powers_bert_en.html":["https://huggingface.co/datasets/lex_glue"],"/2023/03/05/legclf_publicity_bert_en.html":["https://huggingface.co/datasets/lex_glue"],"/2023/03/05/legclf_qualifications_bert_en.html":["https://huggingface.co/datasets/lex_glue"],"/2023/03/05/legclf_records_bert_en.html":["https://huggingface.co/datasets/lex_glue"],"/2023/03/05/legclf_releases_bert_en.html":["https://huggingface.co/datasets/lex_glue"],"/2023/03/05/legclf_remedies_bert_en.html":["https://huggingface.co/datasets/lex_glue"],"/2023/03/05/legclf_representations_bert_en.html":["https://huggingface.co/datasets/lex_glue"],"/2023/03/05/legclf_sales_bert_en.html":["https://huggingface.co/datasets/lex_glue"],"/2023/03/05/legclf_sanctions_bert_en.html":["https://huggingface.co/datasets/lex_glue"],"/2023/03/05/legclf_severability_bert_en.html":["https://huggingface.co/datasets/lex_glue"],"/2023/03/05/legclf_solvency_bert_en.html":["https://huggingface.co/datasets/lex_glue"],"/2023/03/05/legclf_specific_performance_bert_en.html":["https://huggingface.co/datasets/lex_glue"],"/2023/03/05/legclf_submission_to_jurisdiction_bert_en.html":["https://huggingface.co/datasets/lex_glue"],"/2023/03/05/legclf_subsidiaries_bert_en.html":["https://huggingface.co/datasets/lex_glue"],"/2023/03/05/legclf_successors_bert_en.html":["https://huggingface.co/datasets/lex_glue"],"/2023/03/05/legclf_survival_bert_en.html":["https://huggingface.co/datasets/lex_glue"],"/2023/03/05/legclf_tax_withholdings_bert_en.html":["https://huggingface.co/datasets/lex_glue"],"/2023/03/05/legclf_taxes_bert_en.html":["https://huggingface.co/datasets/lex_glue"],"/2023/03/05/legclf_terminations_bert_en.html":["https://huggingface.co/datasets/lex_glue"],"/2023/03/05/legclf_terms_bert_en.html":["https://huggingface.co/datasets/lex_glue"],"/2023/03/05/legclf_titles_bert_en.html":["https://huggingface.co/datasets/lex_glue"],"/2023/03/05/legclf_transactions_with_affiliates_bert_en.html":["https://huggingface.co/datasets/lex_glue"],"/2023/03/05/legclf_use_of_proceeds_bert_en.html":["https://huggingface.co/datasets/lex_glue"],"/2023/03/05/legclf_vacations_bert_en.html":["https://huggingface.co/datasets/lex_glue"],"/2023/03/05/legclf_venues_bert_en.html":["https://huggingface.co/datasets/lex_glue"],"/2023/03/05/legclf_vesting_bert_en.html":["https://huggingface.co/datasets/lex_glue"],"/2023/03/05/legclf_waiver_of_jury_trials_bert_en.html":["https://huggingface.co/datasets/lex_glue"],"/2023/03/05/legclf_waivers_bert_en.html":["https://huggingface.co/datasets/lex_glue"],"/2023/03/05/legclf_warranties_bert_en.html":["https://huggingface.co/datasets/lex_glue"],"/2023/03/05/legclf_withholdings_bert_en.html":["https://huggingface.co/datasets/lex_glue"],"/2023/03/06/legclf_africa_bert_en.html":["https://huggingface.co/datasets/lex_glue"],"/2023/03/06/legclf_agricultural_activity_bert_en.html":["https://huggingface.co/datasets/lex_glue"],"/2023/03/06/legclf_agricultural_policy_bert_en.html":["https://huggingface.co/datasets/lex_glue"],"/2023/03/06/legclf_agricultural_structures_and_production_bert_en.html":["https://huggingface.co/datasets/lex_glue"],"/2023/03/06/legclf_air_and_space_transport_bert_en.html":["https://huggingface.co/datasets/lex_glue"],"/2023/03/06/legclf_america_bert_en.html":["https://huggingface.co/datasets/lex_glue"],"/2023/03/06/legclf_animal_product_bert_en.html":["https://huggingface.co/datasets/lex_glue"],"/2023/03/06/legclf_asia_and_oceania_bert_en.html":["https://huggingface.co/datasets/lex_glue"],"/2023/03/06/legclf_beverages_and_sugar_bert_en.html":["https://huggingface.co/datasets/lex_glue"],"/2023/03/06/legclf_budget_bert_en.html":["https://huggingface.co/datasets/lex_glue"],"/2023/03/06/legclf_building_and_public_works_bert_en.html":["https://huggingface.co/datasets/lex_glue"],"/2023/03/06/legclf_business_classification_bert_en.html":["https://huggingface.co/datasets/lex_glue"],"/2023/03/06/legclf_business_organisation_bert_en.html":["https://huggingface.co/datasets/lex_glue"],"/2023/03/06/legclf_chemistry_bert_en.html":["https://huggingface.co/datasets/lex_glue"],"/2023/03/06/legclf_civil_law_bert_en.html":["https://huggingface.co/datasets/lex_glue"],"/2023/03/06/legclf_coal_and_mining_industries_bert_en.html":["https://huggingface.co/datasets/lex_glue"],"/2023/03/06/legclf_communications_bert_en.html":["https://huggingface.co/datasets/lex_glue"],"/2023/03/06/legclf_competition_bert_en.html":["https://huggingface.co/datasets/lex_glue"],"/2023/03/06/legclf_criminal_law_bert_en.html":["https://huggingface.co/datasets/lex_glue"],"/2023/03/06/legclf_cultivation_of_agricultural_land_bert_en.html":["https://huggingface.co/datasets/lex_glue"],"/2023/03/06/legclf_defence_bert_en.html":["https://huggingface.co/datasets/lex_glue"],"/2023/03/06/legclf_deterioration_of_the_environment_bert_en.html":["https://huggingface.co/datasets/lex_glue"],"/2023/03/06/legclf_distributive_trades_bert_en.html":["https://huggingface.co/datasets/lex_glue"],"/2023/03/06/legclf_documentation_bert_en.html":["https://huggingface.co/datasets/lex_glue"],"/2023/03/06/legclf_economic_analysis_bert_en.html":["https://huggingface.co/datasets/lex_glue"],"/2023/03/06/legclf_economic_conditions_bert_en.html":["https://huggingface.co/datasets/lex_glue"],"/2023/03/06/legclf_economic_policy_bert_en.html":["https://huggingface.co/datasets/lex_glue"],"/2023/03/06/legclf_electrical_and_nuclear_industries_bert_en.html":["https://huggingface.co/datasets/lex_glue"],"/2023/03/06/legclf_electronics_and_electrical_engineering_bert_en.html":["https://huggingface.co/datasets/lex_glue"],"/2023/03/06/legclf_employment_bert_en.html":["https://huggingface.co/datasets/lex_glue"],"/2023/03/06/legclf_energy_policy_bert_en.html":["https://huggingface.co/datasets/lex_glue"],"/2023/03/06/legclf_environmental_policy_bert_en.html":["https://huggingface.co/datasets/lex_glue"],"/2023/03/06/legclf_eu_finance_bert_en.html":["https://huggingface.co/datasets/lex_glue"],"/2023/03/06/legclf_eu_institutions_and_european_civil_service_bert_en.html":["https://huggingface.co/datasets/lex_glue"],"/2023/03/06/legclf_european_construction_bert_en.html":["https://huggingface.co/datasets/lex_glue"],"/2023/03/06/legclf_executive_power_and_public_service_bert_en.html":["https://huggingface.co/datasets/lex_glue"],"/2023/03/06/legclf_farming_systems_bert_en.html":["https://huggingface.co/datasets/lex_glue"],"/2023/03/06/legclf_financial_institutions_and_credit_bert_en.html":["https://huggingface.co/datasets/lex_glue"],"/2023/03/06/legclf_financing_and_investment_bert_en.html":["https://huggingface.co/datasets/lex_glue"],"/2023/03/06/legclf_fisheries_bert_en.html":["https://huggingface.co/datasets/lex_glue"],"/2023/03/06/legclf_food_technology_bert_en.html":["https://huggingface.co/datasets/lex_glue"],"/2023/03/06/legclf_foodstuff_bert_en.html":["https://huggingface.co/datasets/lex_glue"],"/2023/03/06/legclf_free_movement_of_capital_bert_en.html":["https://huggingface.co/datasets/lex_glue"],"/2023/03/06/legclf_health_bert_en.html":["https://huggingface.co/datasets/lex_glue"],"/2023/03/06/legclf_industrial_structures_and_policy_bert_en.html":["https://huggingface.co/datasets/lex_glue"],"/2023/03/06/legclf_information_and_information_processing_bert_en.html":["https://huggingface.co/datasets/lex_glue"],"/2023/03/06/legclf_information_technology_and_data_processing_bert_en.html":["https://huggingface.co/datasets/lex_glue"],"/2023/03/06/legclf_international_affairs_bert_en.html":["https://huggingface.co/datasets/lex_glue"],"/2023/03/06/legclf_international_law_bert_en.html":["https://huggingface.co/datasets/lex_glue"],"/2023/03/06/legclf_international_security_bert_en.html":["https://huggingface.co/datasets/lex_glue"],"/2023/03/06/legclf_iron_steel_and_other_metal_industries_bert_en.html":["https://huggingface.co/datasets/lex_glue"],"/2023/03/06/legclf_labour_market_bert_en.html":["https://huggingface.co/datasets/lex_glue"],"/2023/03/06/legclf_land_transport_bert_en.html":["https://huggingface.co/datasets/lex_glue"],"/2023/03/06/legclf_leather_and_textile_industries_bert_en.html":["https://huggingface.co/datasets/lex_glue"],"/2023/03/06/legclf_management_bert_en.html":["https://huggingface.co/datasets/lex_glue"],"/2023/03/06/legclf_maritime_and_inland_waterway_transport_bert_en.html":["https://huggingface.co/datasets/lex_glue"],"/2023/03/06/legclf_marketing_bert_en.html":["https://huggingface.co/datasets/lex_glue"],"/2023/03/06/legclf_means_of_agricultural_production_bert_en.html":["https://huggingface.co/datasets/lex_glue"],"/2023/03/06/legclf_mechanical_engineering_bert_en.html":["https://huggingface.co/datasets/lex_glue"],"/2023/03/06/legclf_miscellaneous_industries_bert_en.html":["https://huggingface.co/datasets/lex_glue"],"/2023/03/06/legclf_monetary_economics_bert_en.html":["https://huggingface.co/datasets/lex_glue"],"/2023/03/06/legclf_monetary_relations_bert_en.html":["https://huggingface.co/datasets/lex_glue"],"/2023/03/06/legclf_national_accounts_bert_en.html":["https://huggingface.co/datasets/lex_glue"],"/2023/03/06/legclf_natural_and_applied_sciences_bert_en.html":["https://huggingface.co/datasets/lex_glue"],"/2023/03/06/legclf_natural_environment_bert_en.html":["https://huggingface.co/datasets/lex_glue"],"/2023/03/06/legclf_oil_industry_bert_en.html":["https://huggingface.co/datasets/lex_glue"],"/2023/03/06/legclf_organisation_of_transport_bert_en.html":["https://huggingface.co/datasets/lex_glue"],"/2023/03/06/legclf_organisation_of_work_and_working_conditions_bert_en.html":["https://huggingface.co/datasets/lex_glue"],"/2023/03/06/legclf_overseas_countries_and_territories_bert_en.html":["https://huggingface.co/datasets/lex_glue"],"/2023/03/06/legclf_personnel_management_and_staff_remuneration_bert_en.html":["https://huggingface.co/datasets/lex_glue"],"/2023/03/06/legclf_plant_product_bert_en.html":["https://huggingface.co/datasets/lex_glue"],"/2023/03/06/legclf_political_framework_bert_en.html":["https://huggingface.co/datasets/lex_glue"],"/2023/03/06/legclf_politics_and_public_safety_bert_en.html":["https://huggingface.co/datasets/lex_glue"],"/2023/03/06/legclf_prices_bert_en.html":["https://huggingface.co/datasets/lex_glue"],"/2023/03/06/legclf_processed_agricultural_produce_bert_en.html":["https://huggingface.co/datasets/lex_glue"],"/2023/03/06/legclf_public_finance_and_budget_policy_bert_en.html":["https://huggingface.co/datasets/lex_glue"],"/2023/03/06/legclf_regions_and_regional_policy_bert_en.html":["https://huggingface.co/datasets/lex_glue"],"/2023/03/06/legclf_regions_of_eu_member_states_bert_en.html":["https://huggingface.co/datasets/lex_glue"],"/2023/03/06/legclf_research_and_intellectual_property_bert_en.html":["https://huggingface.co/datasets/lex_glue"],"/2023/03/06/legclf_rights_and_freedoms_bert_en.html":["https://huggingface.co/datasets/lex_glue"],"/2023/03/06/legclf_social_affairs_bert_en.html":["https://huggingface.co/datasets/lex_glue"],"/2023/03/06/legclf_social_protection_bert_en.html":["https://huggingface.co/datasets/lex_glue"],"/2023/03/06/legclf_tariff_policy_bert_en.html":["https://huggingface.co/datasets/lex_glue"],"/2023/03/06/legclf_taxation_bert_en.html":["https://huggingface.co/datasets/lex_glue"],"/2023/03/06/legclf_technology_and_technical_regulations_bert_en.html":["https://huggingface.co/datasets/lex_glue"],"/2023/03/06/legclf_trade_bert_en.html":["https://huggingface.co/datasets/lex_glue"],"/2023/03/06/legclf_transport_policy_bert_en.html":["https://huggingface.co/datasets/lex_glue"],"/2023/03/06/legclf_united_nations_bert_en.html":["https://huggingface.co/datasets/lex_glue"],"/2023/03/06/legclf_wood_industry_bert_en.html":["https://huggingface.co/datasets/lex_glue"],"/2023/03/08/legmulticlf_unfair_tos_en.html":["https://github.com/coastalcph/lex-glue"],"/2023/03/09/finner_responsibility_reports_en.html":[],"/2023/03/09/legmulticlf_mnda_sections_paragraph_other_en.html":[],"/2023/03/10/finclf_10k_items_en.html":["https://huggingface.co/datasets/JanosAudran/financial-reports-sec"],"/2023/03/10/finclf_twitter_news_en.html":["https://huggingface.co/datasets/zeroshot/twitter-financial-news-topic"],"/2023/03/10/legclf_reddit_advice_en.html":["https://huggingface.co/datasets/jonathanli/legal-advice-reddit"],"/2023/03/10/finner_financial_xlarge_en.html":[],"/2023/03/11/finassertion_increase_decrease_amounts_en.html":[],"/2023/03/25/summarizer_clinical_jsl.html":[],"/2023/03/25/summarizer_clinical_jsl_en.html":[],"/2023/03/26/sbiobertresolve_hgnc_en.html":["https://evs.nci.nih.gov/ftp1/NCI_Thesaurus/"],"/2023/03/26/sbiobertresolve_ncit_en.html":["https://evs.nci.nih.gov/ftp1/NCI_Thesaurus/"],"/2023/03/26/legclf_argument_mining_en.html":["https://huggingface.co/datasets/MeilingShi/legal_argument_mining"],"/2023/03/26/legclf_argument_mining_german_de.html":["https://huggingface.co/datasets/MeilingShi/legal_argument_mining"],"/2023/03/27/legclf_critical_prediction_italian_it.html":["https://huggingface.co/datasets/rcds/legal_criticality_prediction"],"/2023/03/27/legclf_critical_prediction_legal_de.html":["https://huggingface.co/datasets/rcds/legal_criticality_prediction"],"/2023/03/27/finclf_bert_company_sentiments_es.html":["https://codalab.lisn.upsaclay.fr/competitions/10052learn_the_details"],"/2023/03/27/finclf_bert_consumer_sentiments_es.html":["https://codalab.lisn.upsaclay.fr/competitions/10052learn_the_details"],"/2023/03/27/finclf_bert_target_sentiments_es.html":["https://codalab.lisn.upsaclay.fr/competitions/10052learn_the_details"],"/2023/03/27/finner_bert_target_es.html":["https://codalab.lisn.upsaclay.fr/competitions/10052learn_the_details"],"/2023/03/27/finner_broker_reports_specific_sm_en.html":[],"/2023/03/29/legclf_law_area_prediction_french_fr.html":["https://huggingface.co/datasets/rcds/legal_criticality_prediction"],"/2023/03/29/legclf_law_area_prediction_german_de.html":["https://huggingface.co/datasets/rcds/legal_criticality_prediction"],"/2023/03/29/legclf_law_area_prediction_italian_it.html":["https://huggingface.co/datasets/rcds/legal_criticality_prediction"],"/2023/03/30/summarizer_clinical_jsl_augmented_en.html":[],"/2023/03/30/ner_vop_wip_en.html":[],"/2023/04/01/legmulticlf_multieurlex_english_combined_2_en.html":["https://huggingface.co/datasets/nlpaueb/multi_eurlex"],"/2023/04/01/legmulticlf_multieurlex_english_combined_en.html":["https://huggingface.co/datasets/nlpaueb/multi_eurlex"],"/2023/04/01/legmulticlf_multieurlex_french_combined_fr.html":["https://huggingface.co/datasets/nlpaueb/multi_eurlex"],"/2023/04/01/legmulticlf_multieurlex_german_combined_de.html":["https://huggingface.co/datasets/nlpaueb/multi_eurlex"],"/2023/04/01/legmulticlf_multieurlex_greek_combined_el.html":["https://huggingface.co/datasets/nlpaueb/multi_eurlex"],"/2023/04/01/legmulticlf_multieurlex_slovak_combined_sk.html":["https://huggingface.co/datasets/nlpaueb/multi_eurlex"],"/2023/04/02/ner_jsl_limited_80p_for_benchmarks_en.html":["https://www.johnsnowlabs.com/data/"],"/2023/04/06/legner_nda_applicable_law_en.html":[],"/2023/04/06/legner_nda_confidential_information_permissions_en.html":[],"/2023/04/06/legner_nda_dispute_resolution_en.html":[],"/2023/04/06/legner_nda_exceptions_en.html":[],"/2023/04/06/legner_nda_preamble_en.html":[],"/2023/04/06/legner_nda_termination_en.html":[],"/2023/04/07/legclf_nda_assigments_en.html":[],"/2023/04/07/legclf_nda_non_compete_items_en.html":[],"/2023/04/07/legclf_nda_perpetuity_en.html":[],"/2023/04/07/legner_nda_assigment_en.html":[],"/2023/04/10/legner_nda_def_conf_info_en.html":[],"/2023/04/10/legner_nda_names_of_parties_en.html":[],"/2023/04/10/legner_nda_non_compete_en.html":[],"/2023/04/10/legner_nda_non_solicitation_en.html":[],"/2023/04/10/genericclassifier_sdoh_housing_insecurity_sbiobert_cased_mli_en.html":[],"/2023/04/10/genericclassifier_sdoh_mental_health_clinical_en.html":[],"/2023/04/10/genericclassifier_sdoh_under_treatment_sbiobert_cased_mli_en.html":[],"/2023/04/11/legner_nda_confidential_information_restricted_en.html":[],"/2023/04/12/legmulticlf_covid19_exceptions_english_en.html":["https://huggingface.co/datasets/joelito/covid19_emergency_event"],"/2023/04/12/ner_sdoh_emb_clinical_large_wip_en.html":[],"/2023/04/12/ner_sdoh_emb_clinical_medium_wip_en.html":[],"/2023/04/12/ner_vop_emb_clinical_large_wip_en.html":[],"/2023/04/12/ner_vop_emb_clinical_medium_wip_en.html":[],"/2023/04/13/legmulticlf_covid19_exceptions_french_fr.html":["https://huggingface.co/datasets/joelito/covid19_emergency_event"],"/2023/04/13/finner_sec_edgar_en.html":[],"/2023/04/13/legner_sec_edgar_en.html":[],"/2023/04/13/finsum_flant5_finetuned_sec10k_en.html":[],"/2023/04/14/legclf_court_decisions_unanimity_pt.html":["https://huggingface.co/datasets/joelito/brazilian_court_decisions"],"/2023/04/14/legsum_flant5_legal_augmented_en.html":[],"/2023/04/16/legner_nda_remedies_en.html":[],"/2023/04/17/ner_sdoh_emb_clinical_large_wip_en.html":[],"/2023/04/19/legner_nda_return_of_conf_info_en.html":[],"/2023/04/20/legmulticlf_covid19_exceptions_italian_it.html":["https://huggingface.co/datasets/joelito/covid19_emergency_event"],"/2023/04/20/ner_vop_anatomy_wip_en.html":[],"/2023/04/20/ner_vop_clinical_dept_wip_en.html":[],"/2023/04/20/ner_vop_demographic_wip_en.html":[],"/2023/04/20/ner_vop_problem_reduced_wip_en.html":[],"/2023/04/20/ner_vop_problem_wip_en.html":[],"/2023/04/20/ner_vop_temporal_wip_en.html":[],"/2023/04/20/ner_vop_test_wip_en.html":[],"/2023/04/20/ner_vop_treatment_wip_en.html":[],"/2023/04/24/legner_nda_req_discl_en.html":[],"/2023/04/25/legner_greek_legislation_el.html":[],"/2023/04/26/legmulticlf_online_terms_of_service_english_en.html":["https://huggingface.co/datasets/joelito/online_terms_of_service"],"/2023/04/26/legner_mapa_bg.html":["https://huggingface.co/datasets/joelito/mapa"],"/2023/04/26/legner_mapa_da.html":["https://huggingface.co/datasets/joelito/mapa"],"/2023/04/26/finner_bert_suspicious_activity_reports_en.html":[],"/2023/04/27/legner_mapa_de.html":["https://huggingface.co/datasets/joelito/mapa"],"/2023/04/27/legner_mapa_el.html":["https://huggingface.co/datasets/joelito/mapa"],"/2023/04/27/legner_mapa_en.html":["https://huggingface.co/datasets/joelito/mapa"],"/2023/04/27/legner_mapa_es.html":["https://huggingface.co/datasets/joelito/mapa"],"/2023/04/27/legner_mapa_fr.html":["https://huggingface.co/datasets/joelito/mapa"],"/2023/04/27/legner_mapa_it.html":["https://huggingface.co/datasets/joelito/mapa"],"/2023/04/27/legner_mapa_lt.html":["https://huggingface.co/datasets/joelito/mapa"],"/2023/04/27/legner_mapa_nl.html":["https://huggingface.co/datasets/joelito/mapa"],"/2023/04/27/legner_mapa_pt.html":["https://huggingface.co/datasets/joelito/mapa"],"/2023/04/27/legner_mapa_ro.html":["https://huggingface.co/datasets/joelito/mapa"],"/2023/04/27/genericclassifier_sdoh_housing_insecurity_sbiobert_cased_mli_en.html":[],"/2023/04/27/genericclassifier_sdoh_insurance_status_sbiobert_cased_mli_en.html":[],"/2023/04/27/genericclassifier_sdoh_under_treatment_sbiobert_cased_mli_en.html":[],"/2023/04/27/ner_sdoh_emb_clinical_medium_wip_en.html":[],"/2023/04/28/legner_mapa_cs.html":["https://huggingface.co/datasets/joelito/mapa"],"/2023/04/28/legner_mapa_fi.html":["https://huggingface.co/datasets/joelito/mapa"],"/2023/04/28/legner_mapa_ga.html":["https://huggingface.co/datasets/joelito/mapa"],"/2023/04/28/legner_mapa_sk.html":["https://huggingface.co/datasets/joelito/mapa"],"/2023/04/28/fingen_flant5_finetuned_sec10k_en.html":[],"/2023/04/28/genericclassifier_sdoh_insurance_coverage_sbiobert_cased_mli_en.html":[],"/2023/04/28/genericclassifier_sdoh_insurance_type_sbiobert_cased_mli_en.html":[],"/2023/04/29/leggen_flant5_finetuned_en.html":[],"/2023/05/04/classifier_logreg_ade_en.html":["https://www.sciencedirect.com/science/article/pii/S1532046412000615"],"/2023/05/04/classifierml_ade_en.html":["https://www.sciencedirect.com/science/article/pii/S1532046412000615"],"/2023/05/08/summarizer_clinical_guidelines_large_en.html":[],"/2023/05/09/generic_logreg_classifier_ade_en.html":["https://www.sciencedirect.com/science/article/pii/S1532046412000615"],"/2023/05/09/generic_svm_classifier_ade_en.html":["https://www.sciencedirect.com/science/article/pii/S1532046412000615"],"/2023/05/11/legner_subpoena_en.html":[],"/2023/05/11/classifier_logreg_ade_en.html":["https://www.sciencedirect.com/science/article/pii/S1532046412000615"],"/2023/05/11/classifierml_ade_en.html":["https://www.sciencedirect.com/science/article/pii/S1532046412000615"],"/2023/05/12/ner_abbreviation_emb_clinical_large_en.html":[],"/2023/05/12/ner_abbreviation_emb_clinical_medium_en.html":[],"/2023/05/12/legclf_legal_code_el.html":["https://huggingface.co/datasets/greek_legal_code"],"/2023/05/14/finner_responsibility_reports_md_en.html":[],"/2023/05/15/ner_anatomy_emb_clinical_large_en.html":["https://www.nactem.ac.uk/anatomy/"],"/2023/05/15/ner_anatomy_emb_clinical_medium_en.html":["https://www.nactem.ac.uk/anatomy/"],"/2023/05/16/classifier_logreg_ade_en.html":["https://www.sciencedirect.com/science/article/pii/S1532046412000615"],"/2023/05/16/classifierml_ade_en.html":["https://www.sciencedirect.com/science/article/pii/S1532046412000615"],"/2023/05/17/legclf_nda_non_compete_items_bert_en.html":[],"/2023/05/17/legclf_nda_perpetuity_bert_en.html":[],"/2023/05/19/ner_vop_anatomy_wip_en.html":[],"/2023/05/19/ner_vop_clinical_dept_wip_en.html":[],"/2023/05/19/ner_vop_demographic_wip_en.html":[],"/2023/05/19/ner_vop_problem_reduced_wip_en.html":[],"/2023/05/19/ner_vop_problem_wip_en.html":[],"/2023/05/19/ner_vop_temporal_wip_en.html":[],"/2023/05/19/ner_vop_test_wip_en.html":[],"/2023/05/19/ner_vop_treatment_wip_en.html":[],"/2023/05/19/ner_vop_wip_embeddings_clinical_large_en.html":[],"/2023/05/19/ner_vop_wip_embeddings_clinical_medium_en.html":[],"/2023/05/19/ner_vop_wip_en.html":[],"/2023/05/20/sbiobertresolve_icd10cm_augmented_en.html":["https://www.cdc.gov/nchs/icd/icd10cm.htm"],"/2023/05/24/ner_cellular_emb_clinical_large_en.html":["https://www.geniaproject.org/"],"/2023/05/24/ner_cellular_emb_clinical_medium_en.html":["https://www.geniaproject.org/"],"/2023/05/24/finclf_bert_twitter_financial_news_sentiment_en.html":[],"/2023/05/24/finclf_bert_twitter_financial_text_sentiment_en.html":[],"/2023/05/24/bert_sequence_classifier_vop_side_effect_en.html":[],"/2023/05/25/fingen_flant5_finetuned_alpaca_en.html":["https://huggingface.co/datasets/gbharti/finance-alpaca/viewer/gbharti--finance-alpaca"],"/2023/05/25/finclf_bert_twitter_financial_text_sentiment_lg_en.html":[],"/2023/05/29/fingen_flant5_finetuned_fiqa_en.html":["https://huggingface.co/datasets/BeIR/fiqa"],"/2023/05/29/finqa_flant5_finetuned_en.html":[],"/2023/05/29/legqa_flant5_finetuned_en.html":[],"/2023/05/29/ner_deid_subentity_ar.html":[],"/2023/05/30/genericclassifier_sdoh_housing_insecurity_sbiobert_cased_mli_en.html":[],"/2023/05/30/genericclassifier_sdoh_under_treatment_sbiobert_cased_mli_en.html":[],"/2023/05/30/ner_deid_generic_ar.html":[],"/2023/06/05/legclf_subpoena_en.html":[],"/2023/06/06/ner_vop_anatomy_emb_clinical_large_en.html":[],"/2023/06/06/ner_vop_anatomy_en.html":[],"/2023/06/06/ner_vop_clinical_dept_emb_clinical_large_en.html":[],"/2023/06/06/ner_vop_clinical_dept_emb_clinical_medium_en.html":[],"/2023/06/06/ner_vop_clinical_dept_en.html":[],"/2023/06/06/ner_vop_demographic_emb_clinical_large_en.html":[],"/2023/06/06/ner_vop_demographic_emb_clinical_medium_en.html":[],"/2023/06/06/ner_vop_demographic_en.html":[],"/2023/06/06/ner_vop_emb_clinical_large_en.html":[],"/2023/06/06/ner_vop_emb_clinical_medium_en.html":[],"/2023/06/06/ner_vop_en.html":[],"/2023/06/06/ner_vop_problem_emb_clinical_large_en.html":[],"/2023/06/06/ner_vop_problem_emb_clinical_medium_en.html":[],"/2023/06/06/ner_vop_problem_en.html":[],"/2023/06/06/ner_vop_temporal_emb_clinical_large_final_en.html":[],"/2023/06/06/ner_vop_temporal_emb_clinical_medium_en.html":[],"/2023/06/06/ner_vop_temporal_en.html":[],"/2023/06/06/ner_vop_test_emb_clinical_large_en.html":[],"/2023/06/06/ner_vop_test_emb_clinical_medium_en.html":[],"/2023/06/06/ner_vop_test_en.html":[],"/2023/06/06/ner_vop_treatment_emb_clinical_large_en.html":[],"/2023/06/06/ner_vop_treatment_emb_clinical_medium_en.html":[],"/2023/06/06/ner_vop_treatment_en.html":[],"/2023/06/07/ner_vop_anatomy_emb_clinical_medium_en.html":[],"/2023/06/07/ner_vop_problem_reduced_emb_clinical_large_en.html":[],"/2023/06/07/ner_vop_problem_reduced_emb_clinical_medium_en.html":[],"/2023/06/07/ner_vop_problem_reduced_en.html":[],"/2023/06/08/ner_demographic_extended_healthcare_en.html":[],"/2023/06/13/ner_sdoh_en.html":[],"/2023/06/13/bert_sequence_classifier_vop_drug_side_effect_en.html":[],"/2023/06/13/bert_sequence_classifier_vop_hcp_consult_en.html":[],"/2023/06/13/bert_sequence_classifier_vop_self_report_en.html":[],"/2023/06/13/bert_sequence_classifier_vop_sound_medical_en.html":[],"/2023/07/02/ner_sdoh_access_to_healthcare_en.html":[],"/2023/07/02/ner_sdoh_community_condition_en.html":[],"/2023/07/02/ner_sdoh_demographics_en.html":[],"/2023/07/02/ner_sdoh_health_behaviours_problems_en.html":[],"/2023/07/02/ner_sdoh_income_social_status_en.html":[],"/2023/07/02/ner_sdoh_social_environment_en.html":[],"/2023/07/02/ner_sdoh_substance_usage_en.html":[],"/2023/07/04/multiclassifierdl_hoc_en.html":["https://github.com/qingyu-qc/gpt_bionlp_benchmark/tree/main/Benchmarks/Hoc"],"/2023/07/04/multiclassifierdl_litcovid_en.html":["https://github.com/qingyu-qc/gpt_bionlp_benchmark/tree/main/Benchmarks/LitCovid"],"/2023/07/06/clinical_notes_qa_base_en.html":[],"/2023/07/09/bert_sequence_classifier_patient_urgency_en.html":[],"/2023/07/11/dit_base_finetuned_rvlcdip_en_3_2.html":[],"/2023/07/11/image_text_detector_dit_en_3_2.html":[],"/2023/07/26/ner_section_header_diagnosis_en.html":[],"/2023/07/28/ner_posology_langtest_en.html":[],"/2023/07/31/ner_ade_clinical_langtest_en.html":[],"/2023/07/31/ner_jsl_langtest_en.html":[],"/2023/08/01/sbiobertresolve_loinc_augmented_en.html":[],"/2023/08/04/legclf_law_stack_exchange_en.html":["https://huggingface.co/datasets/jonathanli/law-stack-exchange"],"/2023/08/07/legner_bert_subpoenas_sm_en.html":[],"/2023/08/08/icd10cm_ms_drg_mapper_en.html":["https://www.icd10data.com/ICD10CM/DRG/Amp"],"/2023/08/13/assertion_sdoh_wip_en.html":[],"/2023/08/13/genericclassifier_sdoh_transportation_insecurity_e5_large_en.html":[],"/2023/08/13/genericclassifier_sdoh_transportation_insecurity_sbiobert_cased_mli_en.html":[],"/2023/08/16/bert_sequence_classifier_age_group_en.html":[],"/2023/08/16/genericclassifier_age_group_sbiobert_cased_mli_en.html":[],"/2023/08/17/clinical_notes_qa_base_onnx_en.html":[],"/2023/08/17/clinical_notes_qa_large_onnx_en.html":[],"/2023/08/17/assertion_vop_3cl_emb_clinical_en.html":[],"/2023/08/17/assertion_vop_3cl_emb_clinical_medium_en.html":[],"/2023/08/17/assertion_vop_clinical_en.html":[],"/2023/08/17/assertion_vop_clinical_medium_en.html":[],"/2023/08/17/few_shot_classifier_age_group_sbiobert_cased_mli_en.html":[],"/2023/08/30/few_shot_classifier_patient_complaint_sbiobert_cased_mli_en.html":[],"/2023/08/31/ner_events_clinical_langtest_en.html":[],"/2023/08/31/bert_sequence_classifier_patient_complaint_en.html":[],"/2023/08/31/genericclassifier_patient_complaint_sbiobert_cased_mli_en.html":[],"/2023/08/31/patient_complaint_classifier_generic_bert_M1_en.html":[],"/2023/09/03/ner_oncology_anatomy_general_langtest_en.html":[],"/2023/09/03/ner_oncology_anatomy_granular_langtest_en.html":[],"/2023/09/03/ner_oncology_demographics_langtest_en.html":[],"/2023/09/04/ner_oncology_posology_langtest_en.html":[],"/2023/09/04/ner_oncology_response_to_treatment_langtest_en.html":[],"/2023/09/04/leggen_flant5_mpre_en.html":[],"/2023/09/04/legqa_flant5_mpre_en.html":[],"/2023/09/14/lilt_roberta_funsd_v1_en_3_2.html":[],"/2023/09/14/lilt_rvl_cdip_296K_en_3_2.html":[],"/2023/09/19/genericclassifier_sdoh_financial_insecurity_mpnet_en.html":[],"/2023/09/19/genericclassifier_sdoh_food_insecurity_mpnet_en.html":[],"/2023/09/20/bert_sequence_classifier_vop_adverse_event_en.html":[],"/2023/09/21/ner_vop_anatomy_langtest_en.html":[],"/2023/09/21/ner_vop_clinical_dept_langtest_en.html":[],"/2023/09/21/ner_vop_demographic_langtest_en.html":[],"/2023/09/21/ner_vop_problem_langtest_en.html":[],"/2023/09/22/ner_eu_clinical_condition_langtest_en.html":[],"/2023/09/22/ner_oncology_biomarker_langtest_en.html":[],"/2023/09/22/ner_oncology_diagnosis_langtest_en.html":[],"/2023/09/22/ner_oncology_test_langtest_en.html":[],"/2023/09/22/ner_oncology_therapy_langtest_en.html":[],"/2023/09/22/ner_oncology_tnm_langtest_en.html":[],"/2023/09/22/ner_oncology_unspecific_posology_langtest_en.html":[],"/2023/09/22/ner_vop_problem_reduced_langtest_en.html":[],"/2023/09/22/ner_vop_temporal_langtest_en.html":[],"/2023/09/22/ner_vop_test_langtest_en.html":[],"/2023/09/22/ner_vop_treatment_langtest_en.html":[],"/2023/09/26/ner_clinical_langtest_en.html":["https://portal.dbmi.hms.harvard.edu/projects/n2c2-nlp/"],"/2023/09/26/ner_deid_generic_augmented_langtest_en.html":[],"/2023/09/26/ner_deid_subentity_augmented_langtest_en.html":[],"/2023/10/03/multiclassifierdl_respiratory_disease_en.html":[],"/2023/10/04/legmulticlf_law_stack_exchange_en.html":["https://huggingface.co/datasets/ymoslem/Law-StackExchange"],"/2023/10/06/finassertion_absa_sm_en.html":[],"/2023/10/06/finembedding_e5_base_en.html":[],"/2023/10/06/finner_absa_sm_en.html":[],"/2023/10/10/ner_biomarker_langtest_en.html":[],"/2023/10/10/ner_bionlp_langtest_en.html":["https://aclanthology.org/W13-2008/"],"/2023/10/10/ner_clinical_large_langtest_en.html":["https://portal.dbmi.hms.harvard.edu/projects/n2c2-nlp/"],"/2023/10/10/ner_living_species_langtest_en.html":["https://temu.bsc.es/livingner/2022/05/03/multilingual-corpus/"],"/2023/10/10/ner_vop_langtest_en.html":[],"/2023/10/12/ner_chemprot_clinical_langtest_en.html":["https://biocreative.bioinformatics.udel.edu/"],"/2023/10/15/ner_cellular_langtest_en.html":["https://www.geniaproject.org/"],"/2023/10/15/ner_deid_enriched_langtest_en.html":["https://portal.dbmi.hms.harvard.edu/projects/n2c2-2014/"],"/2023/10/15/ner_deid_large_langtest_en.html":["https://portal.dbmi.hms.harvard.edu/projects/n2c2-2014/"],"/2023/10/15/ner_diseases_langtest_en.html":["https://portal.dbmi.hms.harvard.edu/projects/n2c2-nlp/"],"/2023/10/15/ner_oncology_langtest_en.html":[],"/2023/10/16/multiclassifierdl_heart_disease_en.html":[],"/2023/10/16/multiclassifierdl_mental_disorder_en.html":[],"/2023/10/16/ner_deid_generic_augmented_allUpperCased_langtest_en.html":[],"/2023/11/05/legembedding_e5_base_en.html":[],"/2023/11/06/ner_risk_factors_langtest_en.html":["https://portal.dbmi.hms.harvard.edu/projects/n2c2-2014/"],"/2023/11/09/finembedding_e5_large_en.html":[],"/2023/11/10/legembeddings_bge_base_en.html":[],"/2023/12/07/finembeddings_bge_base_en.html":[],"/2023/12/20/bert_sequence_classifier_sdoh_frailty_vulnerability_en.html":[],"/2023/12/20/bert_sequence_classifier_sdoh_mental_health_en.html":[],"/2023/12/20/bert_sequence_classifier_sdoh_violence_abuse_en.html":[],"/2023/12/21/bert_sequence_classifier_clinical_sections_en.html":[],"/2023/12/21/bert_sequence_classifier_clinical_sections_headless_en.html":[],"/2024/01/17/sbiobertresolve_rxnorm_augmented_en.html":[],"/2024/01/17/cpt_procedures_measurements_resolver_pipeline_en.html":[],"/2024/01/17/ner_deid_name_multilingual_xx.html":[],"/2024/01/24/sbiobertresolve_snomed_findings_en.html":[],"/2024/01/26/sbiobertresolve_snomed_findings_en.html":[],"/2024/02/12/genericclassifier_age_e5_en.html":[],"/2024/02/12/ner_deid_multilingual_xx.html":[],"/2024/02/12/ner_deid_name_multilingual_clinical_xx.html":[],"/2024/02/13/ner_snomed_term_en.html":[],"/2024/02/27/cpt_umls_mapper_en.html":[],"/2024/02/27/umls_cpt_mapper_en.html":[],"/2024/03/04/sbiobertresolve_snomed_bodyStructure_en.html":[],"/2024/03/04/sbiobertresolve_snomed_conditions_en.html":[],"/2024/03/05/sbiobertresolve_snomed_no_class_en.html":[],"/2024/03/06/sbiobertresolve_snomed_drug_en.html":[],"/2024/03/14/icd10_meddra_llt_mapper_en.html":[],"/2024/03/14/meddra_llt_icd10_mapper_en.html":[],"/2024/03/15/icd10_meddra_pt_mapper_en.html":[],"/2024/03/15/meddra_pt_icd10_mapper_en.html":[],"/2024/03/18/meddra_llt_pt_mapper_en.html":[],"/2024/03/18/meddra_pt_llt_mapper_en.html":[],"/2024/03/24/sbiobertresolve_meddra_lowest_level_term_en.html":[],"/2024/03/24/sbiobertresolve_meddra_preferred_term_en.html":[],"/2024/03/26/meddra_llt_resolver_pipeline_en.html":[],"/2024/03/26/meddra_pt_resolver_pipeline_en.html":[],"/2024/03/26/bert_sequence_classifier_response_to_treatment_en.html":[],"/2024/03/28/meddra_hlt_pt_mapper_en.html":[],"/2024/03/28/meddra_pt_hlt_mapper_en.html":[],"/2024/04/15/assertion_fewshotclassifier_en.html":[],"/2024/04/17/sbiobertresolve_umls_findings_en.html":["https://www.nlm.nih.gov/research/umls/index.html"],"/2024/04/18/biolordresolve_rxnorm_augmented_en.html":[],"/2024/04/24/sbiobertresolve_umls_major_concepts_en.html":["https://www.nlm.nih.gov/research/umls/index.html"],"/2024/05/05/sbiobertresolve_umls_disease_syndrome_en.html":["https://www.nlm.nih.gov/research/umls/index.html"],"/2024/05/05/sbiobertresolve_umls_general_concepts_en.html":["https://www.nlm.nih.gov/research/umls/index.html"],"/2024/05/06/biolordresolve_rxnorm_augmented_en.html":[],"/2024/05/06/sbiobertresolve_snomed_veterinary_wip_en.html":["https://vtsl.vetmed.vt.edu/extension/"],"/2024/05/06/sbiobertresolve_umls_clinical_drugs_en.html":["https://www.nlm.nih.gov/research/umls/index.html"],"/2024/05/07/biolordresolve_snomed_findings_aux_concepts_en.html":[],"/2024/05/08/biolordresolve_cpt_procedures_measurements_augmented_en.html":[],"/2024/05/15/legner_lener_base_pt.html":["https://paperswithcode.com/sotatask=Token+Classification&dataset=lener_br"],"/2024/05/15/legner_lener_large_pt.html":["https://paperswithcode.com/sotatask=Token+Classification&dataset=lener_br"],"/2024/05/17/finner_deid_sec_fe_en.html":[],"/2024/05/17/finner_sec_edgar_fe_en.html":[],"/2024/05/17/legner_sec_edgar_le_en.html":[],"/2024/05/21/finance_word_embeddings_en.html":[],"/2024/05/21/legal_word_embeddings_en.html":[],"/2024/05/21/legner_deid_le_en.html":[],"/2024/06/07/classifierml_ade_en.html":["https://www.sciencedirect.com/science/article/pii/S1532046412000615"],"/2024/06/07/finner_financial_xlarge_fe_en.html":[],"/2024/06/07/legner_contract_doc_parties_le_en.html":[],"/2024/06/10/ner_oncology_wip_en.html":[],"/2024/06/10/assertion_dl_radiology_en.html":[],"/2024/06/10/finance_bge_base_embeddings_en.html":[],"/2024/06/10/finel_edgar_company_name_fe_en.html":[],"/2024/06/10/finel_nasdaq_company_name_stock_screener_fe_en.html":["https://www.nasdaq.com/market-activity/stocks/screener"],"/2024/06/10/legal_bge_base_embeddings_en.html":[],"/2024/06/10/sbiobertresolve_snomed_veterinary_en.html":["https://vtsl.vetmed.vt.edu/extension/"],"/2024/06/11/finel_names2tickers_fe_en.html":["https://data.world/johnsnowlabs/list-of-companies-in-nasdaq-exchanges"],"/2024/06/12/sbiobertresolve_umls_clinical_drugs_en.html":["https://www.nlm.nih.gov/research/umls/index.html"],"/2024/06/12/sbiobertresolve_umls_disease_syndrome_en.html":["https://www.nlm.nih.gov/research/umls/index.html"],"/2024/06/12/sbiobertresolve_umls_drug_substance_en.html":["https://www.nlm.nih.gov/research/umls/index.html"],"/2024/06/12/sbiobertresolve_umls_findings_en.html":["https://www.nlm.nih.gov/research/umls/index.html"],"/2024/06/12/sbiobertresolve_umls_general_concepts_en.html":["https://www.nlm.nih.gov/research/umls/index.html"],"/2024/06/12/sbiobertresolve_umls_major_concepts_en.html":["https://www.nlm.nih.gov/research/umls/index.html"],"/2024/06/12/finel_tickers2names_fe_en.html":["https://data.world/johnsnowlabs/list-of-companies-in-nasdaq-exchanges"],"/2024/06/18/sbiobertresolve_rxnorm_augmented_en.html":[],"/2024/06/28/legner_subpoenas_sm_en.html":[],"/2024/07/03/assertion_oncology_demographic_binary_en.html":[],"/2024/07/03/assertion_oncology_en.html":[],"/2024/07/03/assertion_oncology_family_history_en.html":[],"/2024/07/03/assertion_oncology_problem_en.html":[],"/2024/07/03/assertion_oncology_response_to_treatment_en.html":[],"/2024/07/03/assertion_oncology_smoking_status_en.html":[],"/2024/07/03/assertion_oncology_test_binary_en.html":[],"/2024/07/03/assertion_oncology_treatment_binary_en.html":[],"/2024/07/03/re_oncology_biomarker_result_en.html":[],"/2024/07/03/re_oncology_en.html":[],"/2024/07/03/re_oncology_granular_en.html":[],"/2024/07/03/re_oncology_location_en.html":[],"/2024/07/03/re_oncology_size_en.html":[],"/2024/07/03/re_oncology_temporal_en.html":[],"/2024/07/03/re_oncology_test_result_en.html":[],"/2024/07/03/redl_oncology_biobert_en.html":[],"/2024/07/03/redl_oncology_biomarker_result_biobert_en.html":[],"/2024/07/03/redl_oncology_granular_biobert_en.html":[],"/2024/07/03/redl_oncology_location_biobert_en.html":[],"/2024/07/03/redl_oncology_size_biobert_en.html":[],"/2024/07/03/redl_oncology_temporal_biobert_en.html":[],"/2024/07/03/redl_oncology_test_result_biobert_en.html":[],"/2024/07/03/assertion_menopause_wip_en.html":[],"/2024/07/03/ner_menopause_core_en.html":[],"/2024/07/04/legmulticlf_edgar_le_en.html":["https://metatext.io/datasets/ledgar,"],"/2024/07/04/legmulticlf_mnda_sections_paragraph_other_le_en.html":[],"/2024/07/27/mpnetresolve_icd10_cms_hcc_2024_midyear_en.html":[],"/2024/08/12/large_fewshot_classifier_ade_en.html":[],"/2024/08/15/large_fewshot_classifier_age_group_en.html":[],"/2024/08/16/ner_cancer_types_wip_en.html":[],"/2024/08/19/sbiobertresolve_icd10cm_augmented_billable_hcc_en.html":[],"/2024/08/19/sbiobertresolve_icd10cm_augmented_en.html":[],"/2024/08/19/sbiobertresolve_icd10cm_slim_billable_hcc_en.html":[],"/2024/08/19/sbiobertresolve_icd10cm_slim_normalized_en.html":[],"/2024/08/22/sbiobertresolve_icd10cm_augmented_billable_hcc_en.html":[],"/2024/08/22/sbiobertresolve_icd10cm_augmented_en.html":[],"/2024/08/22/sbiobertresolve_icd10cm_slim_normalized_en.html":[],"/2024/08/27/finner_sec_10k_summary_fe_en.html":[],"/2024/09/02/sbiobertresolve_meddra_lowest_level_term_en.html":[],"/2024/09/02/sbiobertresolve_meddra_preferred_term_en.html":[],"/2024/09/03/meddra_llt_pt_mapper_en.html":[],"/2024/09/03/meddra_pt_llt_mapper_en.html":[],"/2024/09/04/icd10_meddra_llt_mapper_en.html":[],"/2024/09/04/icd10_meddra_pt_mapper_en.html":[],"/2024/09/04/meddra_llt_icd10_mapper_en.html":[],"/2024/09/04/meddra_pt_icd10_mapper_en.html":[],"/2024/09/05/meddra_hlt_pt_mapper_en.html":[],"/2024/09/05/meddra_llt_snomed_mapper_en.html":[],"/2024/09/05/meddra_pt_hlt_mapper_en.html":[],"/2024/09/05/snomed_meddra_llt_mapper_en.html":[],"/2024/09/06/meddra_llt_resolver_pipeline_en.html":[],"/2024/09/06/meddra_pt_resolver_pipeline_en.html":[],"/2024/09/11/sentence_detector_dl_healthcare_v2_wip_en.html":[],"/2024/09/12/sbiobertresolve_ndc_en.html":[],"/2024/10/07/sbiobertresolve_loinc_augmented_en.html":[],"/2024/10/07/sbiobertresolve_loinc_en.html":[],"/2024/10/07/sbiobertresolve_loinc_numeric_augmented_en.html":[],"/2024/10/08/biolordresolve_loinc_augmented_en.html":[],"/2024/12/02/sbiobertresolve_umls_major_concepts_en.html":["https://www.nlm.nih.gov/research/umls/index.html"],"/2024/12/04/ner_genes_phenotypes_wip_en.html":[],"/2024/12/05/sbiobertresolve_umls_clinical_drugs_en.html":["https://www.nlm.nih.gov/research/umls/index.html"],"/2024/12/05/sbiobertresolve_umls_disease_syndrome_en.html":["https://www.nlm.nih.gov/research/umls/index.html"],"/2024/12/05/sbiobertresolve_umls_drug_substance_en.html":["https://www.nlm.nih.gov/research/umls/index.html"],"/2024/12/05/sbiobertresolve_umls_findings_en.html":["https://www.nlm.nih.gov/research/umls/index.html"],"/2024/12/05/sbiobertresolve_umls_general_concepts_en.html":["https://www.nlm.nih.gov/research/umls/index.html"],"/2024/12/06/biolordresolve_umls_general_concepts_en.html":["https://www.nlm.nih.gov/research/umls/index.html"],"/2024/12/06/umls_clinical_drugs_mapper_en.html":["https://www.nlm.nih.gov/research/umls/index.html"],"/2024/12/09/umls_icd10cm_mapper_en.html":["https://www.nlm.nih.gov/research/umls/index.html"],"/2024/12/10/cpt_umls_mapper_en.html":["https://www.nlm.nih.gov/research/umls/index.html"],"/2024/12/10/icd10cm_umls_mapper_en.html":["https://www.nlm.nih.gov/research/umls/index.html"],"/2024/12/10/umls_cpt_mapper_en.html":["https://www.nlm.nih.gov/research/umls/index.html"],"/2024/12/11/rxnorm_umls_mapper_en.html":["https://www.nlm.nih.gov/research/umls/index.html"],"/2024/12/11/snomed_umls_mapper_en.html":["https://www.nlm.nih.gov/research/umls/index.html"],"/2024/12/11/umls_rxnorm_mapper_en.html":["https://www.nlm.nih.gov/research/umls/index.html"],"/2024/12/11/umls_snomed_mapper_en.html":["https://www.nlm.nih.gov/research/umls/index.html"],"/2024/12/12/mesh_umls_mapper_en.html":["https://www.nlm.nih.gov/research/umls/index.html"],"/2024/12/12/umls_mesh_mapper_en.html":["https://www.nlm.nih.gov/research/umls/index.html"],"/2024/12/16/umls_disease_syndrome_mapper_en.html":["https://www.nlm.nih.gov/research/umls/index.html"],"/2024/12/18/umls_clinical_findings_mapper_en.html":["https://www.nlm.nih.gov/research/umls/index.html"],"/2024/12/18/umls_drug_substance_mapper_en.html":["https://www.nlm.nih.gov/research/umls/index.html"],"/2024/12/18/umls_major_concepts_mapper_en.html":["https://www.nlm.nih.gov/research/umls/index.html"],"/2024/12/19/loinc_umls_mapper_en.html":["https://www.nlm.nih.gov/research/umls/index.html"],"/2024/12/19/umls_loinc_mapper_en.html":["https://www.nlm.nih.gov/research/umls/index.html"],"/2025/01/11/ner_genes_phenotypes_en.html":[],"/2025/01/13/ner_cancer_types_en.html":[],"/2025/01/16/assertion_genomic_abnormality_wip_en.html":[],"/2025/02/14/biolordresolve_snomed_augmented_es.html":[],"/2025/06/04/sbiobertresolve_umls_disease_syndrome_en.html":["https://www.nlm.nih.gov/research/umls/index.html"],"/2025/06/04/sbiobertresolve_umls_findings_en.html":["https://www.nlm.nih.gov/research/umls/index.html"],"/2025/06/05/sbiobertresolve_umls_clinical_drugs_en.html":["https://www.nlm.nih.gov/research/umls/index.html"],"/2025/06/05/sbiobertresolve_umls_general_concepts_en.html":["https://www.nlm.nih.gov/research/umls/index.html"],"/2025/06/07/sbiobertresolve_umls_major_concepts_en.html":["https://www.nlm.nih.gov/research/umls/index.html"],"/2025/06/11/biolordresolve_umls_general_concepts_en.html":["https://www.nlm.nih.gov/research/umls/index.html"],"/2025/06/21/icd10cm_umls_mapper_en.html":["https://www.nlm.nih.gov/research/umls/index.html"],"/2025/06/21/loinc_umls_mapper_en.html":["https://www.nlm.nih.gov/research/umls/index.html"],"/2025/06/21/mesh_umls_mapper_en.html":["https://www.nlm.nih.gov/research/umls/index.html"],"/2025/06/21/rxnorm_umls_mapper_en.html":["https://www.nlm.nih.gov/research/umls/index.html"],"/2025/06/21/snomed_umls_mapper_en.html":["https://www.nlm.nih.gov/research/umls/index.html"],"/2025/06/21/umls_icd10cm_mapper_en.html":["https://www.nlm.nih.gov/research/umls/index.html"],"/2025/06/21/umls_loinc_mapper_en.html":["https://www.nlm.nih.gov/research/umls/index.html"],"/2025/06/21/umls_mesh_mapper_en.html":["https://www.nlm.nih.gov/research/umls/index.html"],"/2025/06/21/umls_rxnorm_mapper_en.html":["https://www.nlm.nih.gov/research/umls/index.html"],"/2025/06/21/umls_snomed_mapper_en.html":["https://www.nlm.nih.gov/research/umls/index.html"],"/2025/06/22/umls_clinical_drugs_mapper_en.html":["https://www.nlm.nih.gov/research/umls/index.html"],"/2025/06/22/umls_clinical_findings_mapper_en.html":["https://www.nlm.nih.gov/research/umls/index.html"],"/2025/06/22/umls_disease_syndrome_mapper_en.html":["https://www.nlm.nih.gov/research/umls/index.html"],"/2025/06/22/umls_drug_substance_mapper_en.html":["https://www.nlm.nih.gov/research/umls/index.html"],"/2025/06/22/umls_major_concepts_mapper_en.html":["https://www.nlm.nih.gov/research/umls/index.html"],"/2025/07/09/ner_vaccine_types_en.html":[],"/2025/07/14/ner_vaccine_types_en.html":[],"/2025/12/05/bgeresolve_cpt_en.html":[],"/2025/12/05/cpt_mapper_en.html":[],"/2025/12/18/sbiobertresolve_umls_findings_en.html":["https://www.nlm.nih.gov/research/umls/index.html"],"/2025/12/19/ner_drugs_large_v2_en.html":[],"/2025/12/22/sbiobertresolve_umls_clinical_drugs_en.html":["https://www.nlm.nih.gov/research/umls/index.html"],"/2025/12/22/sbiobertresolve_umls_disease_syndrome_en.html":["https://www.nlm.nih.gov/research/umls/index.html"],"/2025/12/22/sbiobertresolve_umls_drug_substance_en.html":["https://www.nlm.nih.gov/research/umls/index.html"],"/2025/12/22/sbiobertresolve_umls_general_concepts_en.html":["https://www.nlm.nih.gov/research/umls/index.html"],"/2025/12/22/sbiobertresolve_umls_major_concepts_en.html":["https://www.nlm.nih.gov/research/umls/index.html"],"/2025/12/23/biolordresolve_umls_general_concepts_en.html":["https://www.nlm.nih.gov/research/umls/index.html"],"/2025/12/28/ner_clinical_large_v2_en.html":[],"/2026/01/08/sbiobertresolve_loinc_en.html":[]}